I. Introduction
To use medications properly for treatment of the overweight patient, it is important to start with a framework based on the realities associated with this treatment. These are briefly summarized below:
• Overweight is due to an imbalance between energy intake and energy expenditure.
• Drugs can either reduce food intake or increase energy expenditure.
• Drug treatment does not cure the overweight patient.
• The therapeutic armamentarium of physicians is limited to only a few drugs.
• The use of drugs labors under the negative halo of treatment mishaps.
• Drugs do not work when they are not taken; when drugs are stopped weight regain is the expected outcome.
• Weight loss plateaus during continued treatment when compensatory mechanisms come into play to counterbalance the effect of the drug.
• Monotherapy usually produces weight loss in the range of 10% (5% better than placebo).
• Frustration with the failure to continue to lose weight often leads to discontinuation of therapy and then to weight regain with labeling of the drug as a failure.
Physicians have several strategies for confronting the problems of the overweight patient. The physician can counsel the patient that he or she is concerned about the patient's current level of body weight and can initiate treatment if the patient is interested. Alternatively, if a physician feels uncomfortable with addressing overweight in patients, he or she can ignore the problem and hope that the patient will not raise the issue. Or, finally the physician can wait until the complications of excess weight manifest themselves as diabetes, dyslipidemia, hypertension, or other disorders and then institute appropriate therapy for each of these medical problems. With the current high-quality therapies available to treat diabetes mellitus, dyslipidemia, and hypertension, many physicians would prefer this latter strategy. However, if medical treatment of the overweight patient were more effective, physicians might prefer to treat the excess weight and thus delay the onset of the problems related to overweight. This strategy was the basis for the long-term Diabetes Prevention Program (DPP) 1 and the Swedish Obese Subjects Study. In the DPP, the onset of new cases of diabetes among individuals with impaired glucose tolerance was reduced 55% during an average follow-up of 3.2 years in the group who lost weight compared with the control group who did not lose weight (Knowler et al., 2002) . In the Swedish Obese Subjects Study, the incidence of new cases of diabetes was reduced to zero over 2 years in patients who lost weight and maintained a weight loss of Ն12%, compared with an incidence of 8.5% for new cases of diabetes in those who did not lose weight . Thus, effective treatment of the overweight patient at risk for diabetes or hypertension can reduce the risk of developing these serious diseases in the future.
One reason most physicians are reluctant to treat overweight patients is that the treatments are limited in number and effectiveness. At the time this article was written, there were only two drugs approved by the U.S. Food and Drug Administration for long-term use. As monotherapy, these agents can produce an overall weight loss of 8 to 10% among patients who continue to take the medication for Ͼ6 months. However, to achieve the elimination of new cases of diabetes as noted above, the weight loss needs to exceed 12%, a goal that is not usually achieved with current monotherapy. Thus, there is a great need for new drugs to be used as monotherapy and probably in combinations when prevention fails.
Both physicians and patients know that overweight is a stigmatized disease (Puhl and Brownell, 2003) . One commonly held view is that overweight people are lazy and weak-willed. If fat people just had willpower, they would push themselves away from the table and not be overweight. This widely held view is shared by the public and by health professionals alike. The clamoring of women to be lean and well proportioned supports this view. The declining relative weight of centerfold models in Playboy magazine and of women who are winners of the Miss America contest in the latter part of the 20th century also supports this view. Many physicians just do not like to see overweight patients come into their offices. This attitude poses a major challenge to any efforts to improve the lot of people who are overweight.
There can be both medical and cosmetic (self-image) benefits to weight loss. However, they do not necessarily occur together. For example, a 10% weight loss, which would be clinically significant for a 300-pound (145-kg) person, would only reduce body weight by 30 to 270 pounds, a weight change that many people might not notice and would not be considered a cosmetic success. At the other extreme, a 10% weight loss for an individual weighing 150 pounds would lower his or her weight to 135 pounds, which would have a very positive impact on self-image. We also know that cosmetically significant weight losses may not produce clinically significant effects. After liposuction that removed ϳ7% of body weight, there were no improvements in health-related risk factors. These distinctions are shown in Table 1 .
Three other issues aggravate the problem of treating overweight patients. The first is the "negative halo" that surrounds the use of appetite suppressants because amphetamine is addictive. There was never any evidence that dexfenfluramine was addictive. Nonetheless, the drug was scheduled by the U.S. Drug Enforcement Agency as a Schedule IV drug because, on paper, it had chemical similarities to amphetamine.
The second issue is the concern about the plateau of body weight that is reached when homeostatic mechanisms in the body come into play and stop further weight loss. There is an analogy with treatment of hypertension. When an antihypertensive drug is given, blood pressure drops and then stops falling within a few weeks to reach a plateau at a new lower level. The antihypertensive drug has not lost its effect when the plateau occurs, but its effect is being counteracted by physiological mechanisms designed to maintain blood pressure. In the treatment of overweight patients, a similar plateau in body weight is often viewed as a therapeutic failure for the weight loss drug. This is particularly so when weight is regained after the drug is stopped. These attitudes and biases need to change before any effective new therapy will become widely accepted.
The final issue is the toxicity associated with many antiobesity drugs. The disaster that occurred for some of the patients who took the combination of fenfluramine and phentermine is one example (others are listed in Table 2 ). Aortic regurgitation occurred in up to 25% of the patients treated with this combination of drugs and led many physicians to say, "I told you so" and "I'm certainly glad I didn't use those drugs." This issue has largely subsided with time, but there will always remain a residue of concern among some physicians and among regulators about the potential problems that might sur- face when new treatments for overweight are made available to the public. Although the drug treatment of overweight patients has at least a century-long history (Colman, 2005) , progress in drug discovery was given a new impetus by the discovery of leptin in 1994 (Zhang et al., 1994) . This peptide demonstrated that overweight can be caused by a hormone deficiency and be reversed by replacement of that hormone (Halaas et al., 1995; Maffei et al., 1995; Farooqi et al., 2002) . Even before the discovery of leptin, overweight had been declared to be a chronic disease by a National Institutes of Health Consensus Conference in 1985 (Bray, 2004) . In the 20th century, bad eating habits were considered a primary cause for overweight. Because some bad habits can be behaviorally extinguished over a 12-week period of time, overweight medications approved before 1985 were approved for periods up to 12 weeks as an adjunct to a lifestyle change program. Equating overweight with bad habits and the stigmatization of obesity slowed the use of overweight medications chronically, as is done with medications for other chronic diseases (Puhl and Brownell, 2003) . With the recognition that longer-term therapy was needed, clinical trials have been extended in length. Since 1990, only three medications have been approved for the chronic treatment of overweight, and one of them, dexfenfluramine, was withdrawn 2 years later (Anonymous, 1996) .
II. Using the Currently Available Drugs
In this article, we review the field of drug therapy for the overweight patient. Table 3 lists the drugs that are available and whether they are approved for long-term use by the U.S. Food and Drug Administration or are restricted (scheduled) by the U.S. Drug Enforcement Agency on the basis of the belief that there is risk of abuse from the drug. For individuals desiring more detail or additional guidance in the use of medications to treat overweight, information can be found in a variety of sources ; National Heart, Lung, and Blood Institute and North American Association for the Study of Obesity, 2000; Haddock et al., 2002; Yanovski and Yanovski, 2002; Kim et al., 2003; Padwal et al., 2004 Padwal et al., , 2005 Colman, 2005; Li et al., 2005; Snow et al., 2005; Vettor et al., 2005) .
As a guide for the use of medications, we will use an algorithm that was described by the National Heart, Lung, and Blood Institute. The first step in this algorithm is to measure height, weight, and waist circumference to establish the body mass index (BMI) and the degree of central adiposity. If the BMI, ([weight in kilograms divided by the square of the height in meters] or [weight in pounds divided by square of the height (inches)] ϫ 703] is Ͼ30 kg/m 2 the patient is by definition obese and can be considered for medications. Overweight individuals with a BMI between 27 and 30 kg/m 2 may also be considered if they have diabetes, hypertension, sleep apnea, or another medical condition that would benefit from weight loss.
Waist circumference is also an important indicator of risk from excess fat. The currently recommended upper limit for waist circumference in the United States is 102 cm (40 inches) for a man and 88 cm (35 inches) for a woman. A recent proposal from the International Diabetes Federation requires the presence of central adiposity to diagnose the metabolic syndrome and uses values for waist circumference Ͼ80 cm for females and Ͼ94 cm for males. Another important initial step in evaluating the overweight patient is to assess associated (comorbid) conditions by measuring blood pressure, glucose, lipids and, when indicated, by performing other tests. With results from this laboratory panel and waist circumference, the metabolic syndrome can be diagnosed. This is best done with the criteria from the National Cholesterol Education Panel Adult Treatment III Guidelines (Table 4) .
Once the patient has been established as an appropriate candidate to lose weight and he or she is motivated to do so, the next step is to set a weight loss goal. Most patients have an unrealistic view of how much weight they can lose. For them, a weight loss of Ͻ15% is often viewed as a failure. In contrast, weight loss using monotherapy with the drugs that are currently available is not usually Ͼ10%. It is, thus, important for physician and patient alike to set a weight loss goal for initial therapy that is not Ͼ10% and to set a lower limit for weight loss of Ͻ5%, which will suggest that an alternative strategy is needed.
The next step is to be certain that the patient is "ready" to lose weight. With use of ideas from psychology, the patient must be ready to work on weight loss as opposed to not yet thinking about the problem. Once the weight goal is established and patients are prepared to take charge of their weight loss program, the next steps are to help them develop lifestyle changes that will benefit their program. The most important of these is monitoring what they eat, where they eat it, and under what circumstances they eat. A second element is to provide advice on diet and physical activity. Replacing voluntary choices with "portion-controlled" choices at one or more meals can be helpful. There are frozen foods, ready-to-make food items, and canned meal replacements that can be used for this purpose. Patients also need more exercise. One strategy is to have them get a step-counter and record the number of steps they take with the goal of gradually increasing this number to 10,000 steps/day. In a review of lifestyle treatment used with pharmacotherapy in randomized clinical trials Poston et al. (2001) found that balanced-deficit diets were used in 40.7%, low-calorie diets in 25% and self-monitoring behavioral strategies in 23.1% of patients (Poston et al., 2001) . When a patient returns to you, establish whether he or she has met the goals. If so, the patient continues as is, but if after 3 months he or she fails to meet the goals, then medications may be considered. The next step is to discuss the pros and cons of medication with the patient. An algorithm from the American College of Physicians (Snow et al., 2005) recommends six medications: orlistat, sibutramine, Orlistat is a lipase inhibitor. In pharmacological studies, it was shown to be a potent selective inhibitor of pancreatic lipase and to thus reduce the intestinal digestion of fat. The drug has a dose-dependent effect on fecal fat loss, increasing it to ϳ30%. Thus, orlistat is recommended to be used with a diet that has 30% of its energy as fat. Orlistat has little effect in subjects eating a low-fat diet, as might be anticipated from its mechanism of action. In single-dose randomized and placebo-controlled studies, 120 mg of orlistat was shown to increase glucagon-like peptide-1 (GLP-1) and C-peptide more than placebo (Damci et al., 2004) , to increase fecal fat loss but decrease the acute increase in cholecystokinin (O'Donovan et al., 2003) , but not to influence the behavioral measures of satiety (Goedecke et al., 2003) .
Results of a number of 1-to 2-year long-term clinical trials with orlistat have been published. The results of a 2-year trial are shown in Fig. 1 (Sjostrom et al., 1998) . The trial consisted of two parts. In the 1st year, patients received a hypocaloric diet calculated to be 500 kcal/day less than the patient's requirements. During the 2nd year, the diet was calculated to maintain body weight. By the end of year 1, the placebo-treated patients lost Ϫ6.1% of their initial body weight and the drug-treated patients lost Ϫ10.2%. The patients were randomized again at the end of year 1. Those switched from orlistat to placebo gained weight from Ϫ10 to Ϫ6% below baseline. Those switched from placebo to orlistat lost weight from Ϫ6 to Ϫ8.1% below baseline, which was essentially identical to the Ϫ7.9% weight loss in the patients treated with orlistat for the full 2 years.
In a second 2-year study, 892 patients were randomized to orlistat or placebo (Davidson et al., 1999) . One group received placebo throughout the 2 years (97 patients), and a second group received orlistat (120 mg three times per day) for 2 years (109 patients). At the end of 1 year, the dose for two-thirds of the group treated with orlistat for 1 year was changed to 60 mg three times per day (102 patients), and the others were switched to placebo (95 patients) (Davidson et al., 1999) . After 1 year, the weight loss was Ϫ8.67 kg in the orlistat-treated group and Ϫ5.81 kg in the placebo group (P Ͻ 0.001). During the 2nd year, those switched to placebo after 1 year reached the same weight as those treated with placebo for 2 years (Ϫ4.5% in those treated with placebo for 2 years and Ϫ4.2% in those switched to placebo during year 2).
In a third 2-year study, 783 patients remained in the placebo or orlistat-treated groups at 60 or 120 mg three times per day for the entire 2 years . After 1 year with a weight-loss diet, the placebo group lost Ϫ7 kg, which was significantly less than the Ϫ9.6 kg lost by the group treated with orlistat 60 mg three times daily or the Ϫ9.8 kg lost by the group treated with 120 mg of orlistat three times daily. During the 2nd year, when the diet was liberalized to a "weight maintenance" diet, all three groups regained some weight. At the end of 2 years, the patients in the placebo group were Ϫ4.3 kg below baseline, the patients treated with 60 mg of orlistat three times per day were Ϫ6.8 kg below baseline, and the patients who took 120 mg of orlistat three times per day were Ϫ7.6 kg below baseline.
The final 2-year trial evaluated 796 subjects in a general-practice setting (Hauptman, 2000) . After 1 year of treatment with 120 mg of orlistat three times per day, the orlistat-treated patients (n ϭ 117) lost Ϫ8.8 kg, compared with Ϫ4.3 kg in the placebo group (n ϭ 91). During the 2nd year, when the diet was liberalized to "maintain body weight," both groups regained some weight. At the end of 2 years, the orlistat group was Ϫ5.2 kg below their baseline weight randomized DRUG TREATMENT OF OBESITY compared with Ϫ1.5 kg below baseline for the group treated with placebo.
The pooled 2-year data from these four studies are shown in Fig. 2 . This figure contains information on both the 120-and 60-mg-three-times-a-day doses. It is clear that there is a dose response. The maximal weight loss was achieved between 6 and 9 months, and then there was a slow regain in all of the groups during the rest of the study.
The results of a 4-year double-blind, randomized, placebo-controlled trial with orlistat have also been reported . A total of 3304 overweight patients, 21% of whom had impaired glucose tolerance, were included in this Swedish trial (Fig. 3) . The lowest body weight was achieved during the 1st year: ϾϪ11% below baseline in the orlistat-treated group and 6% below baseline in the placebo-treated group. Over the remaining 3 years of the trial, there was a small regain in weight, such that by the end of 4 years, the orlistat-treated patients were Ϫ6.9% below baseline compared with Ϫ4.1% for those receiving placebo. The trial also showed a 37% reduction in the conversion of patients from impaired glucose tolerance to diabetes; essentially all of this benefit occurred in the patients with impaired glucose tolerance when they were enrolled into the trial.
Weight maintenance with orlistat was evaluated in a 1-year study (Hill et al., 1999) . Patients were enrolled if they had lost Ͼ8% of their body weight over 6 months while eating a 1000 kcal/day (4180 kJ/day) diet. The 729 patients were randomized to receive placebo or orlistat at 30, 60, or 120 mg three times per day for 12 months. At the end of this time, the placebotreated patients regained 56% of their body weight, compared with 32.4% in the group treated with 120 mg of orlistat three times per day. The other two doses of orlistat were no different from placebo in preventing the regain of weight.
c. Studies in special populations. i. Diabetic patients. Patients with diabetes treated with orlistat, 120 mg three times daily for 1 year, lost more weight than the placebo-treated group (Hollander et al., 1998; Kelley et al., 2002; Miles et al., 2002) . The subjects with diabetes also showed a significantly greater decrease in hemoglobin A 1c levels. In another study of orlistat and weight loss, investigators pooled data on 675 subjects from three of the 2-year studies described previously in which glucose tolerance tests were available (Heymsfield et al., 2000) . During treatment, 6.6% of the patients taking orlistat converted from a normal to an impaired glucose tolerance test, compared with 10.8% in the placebo-treated group. None of the orlistat-treated patients who originally had normal glucose tolerance developed diabetes, compared with 1.2% in the placebo-treated group. Of those who initially had normal glucose tolerance, 7.6% in the placebo group but only 3% in the orlistat-treated group developed diabetes.
The effect of orlistat in preventing diabetes has been assessed in a 4-year study . In this trial weight was reduced by 2.8 kg (95% CI 1.1-4.5 kg) compared with placebo, and the conversion rate to diabetes was reduced from 9 to 6% for a relative risk reduction of (Padwal et al., 2005) .
ii. Metabolic syndrome and lipids. In a further analysis, patients who participated in the studies described above were divided into the highest and lowest quintiles for triglycerides and HDL cholesterol levels (Reaven et al., 2001) . Those with high triglyceride and low HDL cholesterol levels were labeled "syndrome X," and those with the lowest triglyceride levels and highest HDL cholesterol levels were the "nonsyndrome X" controls. With this classification, there were almost no men in the nonsyndrome X group, compared with an equal sex breakdown in the syndrome X group. In addition, the syndrome X group had slightly higher systolic and diastolic blood pressure levels and a nearly 2-fold higher level of fasting insulin. Besides weight loss, the only difference between the placebo and orlistat-treated patients was the decrease in LDL cholesterol levels in the FIG. 2 . Two-year pooled data comparing orlistat and 120 and 60 mg three times a day and placebo. From Hoffmann-LaRoche data, with permission from Dr. Jonathan Hauptman. 
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patients treated with orlistat. However, the syndrome X subgroup showed a significantly greater decrease in triglyceride and insulin levels than those without syndrome X. Levels of HDL cholesterol increased more in the syndrome X group, but LDL cholesterol levels showed a smaller decrease than that in the nonsyndrome X group. All of the clinical studies with orlistat have shown significant decreases in serum cholesterol and LDL cholesterol levels that usually are greater than decreases that can be accounted for by weight loss alone . One study showed that orlistat reduces the absorption of cholesterol from the GI tract, thus providing a mechanism for the clinical observations (Mittendorfer et al., 2001) .
iii. Studies in children. A multicenter trial tested the effect of orlistat in 539 obese adolescents (Chanoine et al., 2005) . Subjects were randomized to placebo or 120 mg of orlistat three times a day and a mildly hypocaloric diet containing 30% fat. By the end of the study BMI decreased Ϫ0.55 kg/m 2 in the drug-treated group but increased ϩ0.31 kg/m 2 in the placebo group. By the end of the study, weight increased by only ϩ0.51 kg in the orlistat-treated group, compared with ϩ3.14 kg in the placebo-treated group (Fig. 4) . This difference was due to differences in body fat. The side effects were gastrointestinal in origin, as expected from the mode of action of orlistat. A second small 6-month randomized clinical trial from a single site failed to show a difference resulting from treatment with orlistat in a population of 40 adolescents (Maahs et al., 2006) .
d. Meta-analysis of orlistat studies. Several metaanalyses of orlistat have been published (Haddock et al., 2002; Avenell et al., 2004; Li et al., 2005) . By pooling six studies Haddock et al. (2002) estimated the weight loss in patients treated with orlistat to be Ϫ7.1 kg (range Ϫ4.0 to Ϫ10.3 kg) compared with Ϫ5.02 kg (range Ϫ3.0 to Ϫ6.1 kg) for the placebo-treated groups. In the metaanalysis of Li et al. (2005) , the overall mean difference between orlistat and placebo after 12 months of therapy in 22 studies was Ϫ2.70 kg (95% CI Ϫ3.79 to Ϫ1.61 kg). Because this analysis included diabetic and nondiabetic subjects, we have summarized the data from the five 2-year studies in Table 5 .
In another meta-analysis of orlistat, 8-year-long studies, only one of which was in diabetic subjects, examined the effects of weight loss at 1 and 2 years and on the various laboratory and clinical responses. The overall effect of orlistat on weight loss at 12 months using the weighted mean difference was Ϫ3.01 kg (95% CI Ϫ3.48 to Ϫ2.54 kg) ( Table 6) . After 24 months, the overall effect of orlistat on weight loss was Ϫ3.26 kg (95% CI Ϫ4.15 to Ϫ2.37 kg). In terms of weight maintenance, the overall effect of orlistat after 12 months was Ϫ0.85 kg (95% CI Ϫ1.50 to Ϫ0.19 kg) (Davidson et al., 1999; Hill et al., 1999; Hauptman, 2000; Rossner et al., 2000) . The pooled data show significant overall effects after 1 year of treatment on the change in cholesterol [Ϫ0.34 mM (95% CI Ϫ0.41 to Ϫ0.027)] (n ϭ 7 studies), the change in LDL cholesterol [Ϫ0.29 mM (95% CI Ϫ0.34 to Ϫ0.24)] (n ϭ 7 studies), the change in HDL cholesterol [Ϫ0.03 mM (95% CI Ϫ0.05 to Ϫ0.01)] (n ϭ 6 studies), the change in triglycerides [0.03 mM (95% CI Ϫ0.04 to 0.10)] (n ϭ 6 studies), the change in hemoglobin A1c [Ϫ0.17% (95% CI Ϫ0.24 to Ϫ0.10] (n ϭ 3 studies) (Hollander et al., 1998; Lindgarde, 2000; Broom et al., 2002) , the change in systolic blood pressure [Ϫ2.02 mm Hg (95% CI Ϫ2.87 to Ϫ1.17)] (n ϭ 7 studies), and the change in diastolic blood pressure [Ϫ1.64 mm Hg (95% CI Ϫ2.20 to Ϫ1.09)] (n ϭ 7 studies)]. In a meta-analysis focused on the use of orlistat in diabetics Norris et al. (2004) reported a weighted mean difference in favor of orlistat of Ϫ2.6 kg (95% CI Ϫ3.2 to Ϫ2.1) after 52 to 57 weeks of treatment.
e. Safety considerations. Orlistat is not absorbed to any significant degree from the gastrointestinal tract, and its side effects are thus related to the blockade of triglyceride digestion in the intestine (Zhi et al., 1999) . Fecal fat loss and related GI symptoms are common initially, but they subside as patients learn to use the drug . The quality of life in patients treated with orlistat may improve despite concerns about GI symptoms. Orlistat can cause small but significant decreases in fat-soluble vitamins. Levels usually remain within the normal range, but a few patients may need vitamin supplementation. Because it is impossible to tell which patients need vitamins, it is wise to FIG. 4 Sibutramine is a highly selective inhibitor for the reuptake at nerve endings of norepinephrine and serotonin and, to a lesser degree, dopamine. In preclinical experimental and clinical studies, it reduced food intake. In a double-blind placebocontrolled 2-week trial, a 30-mg/day dose of sibutramine reduced food intake by 23% on day 7 and 26% on day 14 relative to placebo and also decreased the percentage of fat eaten. A smaller dose of 10 mg also significantly reduced food intake at 14 days (Rolls et al., 1998) . The effect of sibutramine on food intake has also been examined over a longer period of time (Barkeling et al., 2003) . The first 2 weeks of this 10-month trial were conducted in a double-blind, randomized, placebo-controlled, crossover design. Participants then entered a 10-month openlabel trial with repeat food intake at the end. There was a 16% reduction in energy intake at the test lunch in the first part of the study (after 2 weeks). Ten months later, there was still a 27% reduction compared with participants' preweight loss placebo-treatment food intake. In animals, sibutramine also stimulates thermogenesis, but there are conflicting data in humans (Hansen et al., 1998; Seagle et al., 1998) . Mechanistic studies have shown that the effect of sibutramine can be mimicked by combining a selective serotonin reuptake inhibitor (fluoxetine) with a selective norepinephrine reuptake inhibitor (nisoxetine). When injected alone these specific reuptake inhibitors do not replicate the reduction of food intake produced by sibutramine (Jackson et al., 1997) . Sibutramine treatment of experimental animals increased the activity of the sympathetic nervous system and attenuated the rise in NPY and fall in POMC in the arcuate nucleus in energy-restricted rats indicating that this drug influences both monoamine and peptidergic pathways involved in food intake (Levin and DunnMeynell, 2000) .
b. Long-term studies.
Sibutramine has been approved by the U.S. Food and Drug Administration for long-term use in the treatment of overweight patients.
Sibutramine has been evaluated extensively in several multicenter trials lasting 6 to 24 months. In a 6-month dose-ranging study of 1047 patients, 67% treated with sibutramine achieved a 5% weight loss from baseline, and 35% lost Ն10% . There was a clear dose-response effect in this 24-week trial, and patients regained weight when the drug was stopped, indicating that the drug remained effective when used. Data from this multicenter trial are shown in Fig. 5 (Bray et al., 1999) . In a 1-year trial of 456 patients who received sibutramine (10 or 15 mg/day) or placebo, 56% of those who stayed in the trial for 12 months lost at least 5% of their initial body weight, and 30% of the patients lost 10% of their initial body weight while taking the 10-mg dose (Smith and Goulder, 2001) .
Three trials have assessed the value of using sibutramine to prevent regain of body weight (Apfelbaum et al., 1999; James et al., 2000; Mathus-Vliegen, 2005) . In a multicenter trial, participants were initially given a very low-calorie diet (VLCD) for 6 weeks to induce weight loss (Apfelbaum et al., 1999) . Of the initial 181 subjects enrolled, 142 were randomized to either 10 mg/day of sibutramine or placebo after losing Ϫ6 kg or more with the VLCD. After another 12 months, those receiving the 
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BRAY AND GREENWAY drug lost an additional 6.4 kg compared with a small weight gain of ϩ0.2 kg for those receiving placebo. The authors concluded that sibutramine had effectively enhanced the initial weight loss and maintained it for an additional 12 months.
This was followed by the Sibutramine Trial of Obesity Reduction and Maintenance (STORM) Trial that lasted 2 years and provided evidence for weight maintenance (James et al., 2000) (Fig. 6) . Seven centers participated in this study, in which patients were initially enrolled in an open-label phase and treated with 10 mg/day of sibutramine for 6 months. Of the patients who lost Ͼ8 kg, two-thirds were then randomized to sibutramine and one-third to placebo. During the 18-month double-blind phase of this trial, the placebo-treated patients steadily regained weight, maintaining only 20% of their weight loss at the end of the trial. In contrast, the subjects treated with sibutramine maintained their weight for 12 months and then regained an average of only 2 kg, thus maintaining 80% of their initial weight loss after 2 years (James et al., 2000) . Despite the higher weight loss with sibutramine at the end of the 18 months of controlled observation, the blood pressure levels of the sibutramine-treated patients were still higher than those of the patients treated with placebo.
The final trial for weight maintenance with sibutramine was a study conducted at eight hospitals in the Netherlands in which patients were initially treated before referral to their primary care physicians. A total of 221 patients began the VLCD. Of these patients, 189 lost the required Ն10 kg during 3 months and were randomized to 10 mg/day of sibutramine or placebo for the remaining 15 months. Mean weight loss during the VLCD period for the successful subjects was 14.5% from baseline. After 2 additional months of treatment in the hospital clinic, the final 13 months were conducted in the general practitioner's offices. At 18 months, the odds ratio was ) favoring weight loss with sibutramine (P ϭ 0.03). With use of the intent-totreat analysis, Ͼ80% of the weight loss at the end of the VLCD was maintained by 70, 51, and 30% of those receiving sibutramine at 6, 12, and 18 months compared with 48, 31, and 20% of those receiving placebo, and these differences were significant at all time points (P Յ 0.03) (Mathus-Vliegen, 2005) .
The possibility of using sibutramine as intermittent therapy has been tested in a randomized, placebo-controlled trial lasting 52 weeks (Wirth and Krause, 2001) (Fig. 7) . The patients randomized to sibutramine received one of two regimens. One group received continuous treatment with 15 mg/day for 1 year, and the other group had two 6-week periods when sibutramine was withdrawn. During the periods when the drug was replaced by placebo, there was a small regain in weight that was lost when the drug was resumed. At the end of the trial, the continuous-therapy and intermittent-therapy groups lost the same amount of weight.
c. Studies in special populations. i. Diabetic patients. The effects of sibutramine in diabetic patients have been examined in eight studies. In a 3-month (12-week) trial, patients with diabetes who were treated with 15 mg/day of sibutramine lost 2.4 kg (2.8%), compared with a loss of 0.1 kg (0.12%) in the placebo group . In this study, hemoglobin A 1c levels decreased 0.3% in the drug-treated group and remained stable in the placebo group. Fasting glucose values decreased 0.3 mg/dl in the drug-treated patients and increased 1.4 mg/dl in the placebo-treated group. In a 24-week trial, the dose of sibutramine was increased from 5 to 20 mg/day over 6 weeks . Among those who completed the treatment, weight loss was Ϫ4.3 kg (4.3%) in the sibutraminetreated patients, compared with Ϫ0.3 kg (0.3%) in placebo-treated patients. Hemoglobin A 1c levels decreased 1.67% in the drug-treated group, compared with 0.53% in the placebo-treated group. These changes in glucose FIG. 6 . Effect of sibutramine on weight maintenance. Adapted from James et al. (2000). 
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and hemoglobin A 1c levels were expected from the amount of weight loss associated with drug treatment.
In a 12-month multicenter, randomized, placebo-controlled study (McNulty et al., 2003) , 194 diabetics receiving metformin were assigned to placebo (n ϭ 64), 15 mg/day of sibutramine (n ϭ 68), or 20 mg/day of sibutramine (n ϭ 62). At 12 months, weight loss in the 15 mg/day group was 5.5 Ϯ 0.6 kg and in the 20 mg/day group it was 8.0 Ϯ 0.9 kg compared with 0.2 Ϯ 0.5 kg in the placebo group. Glycemic control improved in parallel with weight loss. Sibutramine raised sitting diastolic blood pressure by Ͼ5 mm Hg in 43% of those receiving 15 mg/day of sibutramine compared with 25% for the placebo group (P Ͻ 0.05). Pulse rate increased Ͼ10 beats/min in 42% of those receiving sibutramine, compared with 17% for those receiving placebo.
The 2-year trial by Redmon et al. (2005) was a doubleblind, randomized, placebo-controlled trial that had a crossover for the control group after the 1st year. The treatment group received 10 mg/day of sibutramine for the entire 2 years. In addition, they had a portion-controlled diet used for 7 days at the end of each 2 months. There was a significantly greater weight loss in the drug-treated group that reached Ϫ9.7 kg at 12 months, compared with Ϫ1.6 kg in the placebo-treated group. During the 2nd year, those receiving sibutramine continuously regained weight slowly, rising to a maximal loss of Ϫ6.3 kg at 24 months. In contrast, the group that got sibutramine only during the 2nd year weighed less at 24 months than those receiving sibutramine continuously for 2 years (Ϫ6.3 kg in the continuous treatment group versus Ϫ9.7 kg for the crossover group). There was an improvement in diabetic control associated with the weight loss.
A meta-analysis has been done of eight studies in diabetic patients receiving sibutramine (Vettor et al., 2005) . In this meta-analysis, the changes in body weight, waist circumference, glucose, hemoglobin A 1c , triglycerides, and HDL cholesterol favored sibutramine. The mean weight loss was 5.53 Ϯ 2.2 kg for those treated with sibutramine and 0.90 Ϯ 0.17 kg for the placebo-treated patients. There was no significant change in systolic blood pressure, but diastolic blood pressure was significantly higher in the sibutramine-treated patients (Vettor et al., 2005) . In the meta-analysis by Norris et al. (2004) the net weight loss over 12 to 26 weeks in 4 trials, including 391 diabetic patients, was 4.5 kg (95% CI 7.2-1.8 kg).
ii. Hypertensive patients. Some trials have reported the use of sibutramine to treat overweight patients with hypertension. In a 3-month trial, where all patients received ␤-blockers, with or without thiazides, for their hypertension McMahon et al. (2000) reported that sibutramine-treated patients lost 4.2 kg (4.5%), compared with a loss of 0.3 kg (0.3%) in the placebo-treated group. Mean supine and standing diastolic and systolic blood pressure levels were not significantly different between drug-treated and placebo-treated patients. Heart rate, however, increased by 5.6 Ϯ 8.25 beats/min (mean Ϯ S.D.) in the sibutramine-treated patients, compared with an increase of 2.2 Ϯ 6.43 beats/min in the placebo group. In another 52-week trial, patients with hypertension whose blood pressure levels were controlled with calcium channel blockers with or without ␤-blockers or thiazides (McMahon et al., 2000) received sibutramine in doses that were increased from 5 to 20 mg/day during the first 6 weeks. Weight loss was significantly greater in the sibutramine-treated patients, averaging Ϫ4.4 kg (4.7%), compared with Ϫ0.5 kg (0.7%) in the placebotreated group. Diastolic blood pressure levels decreased 1.3 mm Hg in the placebo-treated group and increased ϩ2 mm Hg in the sibutramine-treated group. Systolic blood pressure levels increased ϩ1.5 mm Hg in the placebo-treated group and ϩ2.7 mm Hg in the sibutraminetreated group. Heart rate was unchanged in the placebotreated patients, but increased by ϩ4.9 beats/min in the sibutramine-treated patients.
The effects of sibutramine on blood pressure have been evaluated in a meta-analysis of 21 studies by Kim et al. (2003) . Sibutramine produced a significant overall weight loss and a significant increase in both systolic and diastolic blood pressures. In a subgroup analysis, they found the effect on systolic blood pressure to be greater with higher doses of sibutramine, in individuals weighing Ն92 kg and in younger individuals (Ͻ44 years of age). Older individuals with body weights of Ն92 kg also showed a greater rise in diastolic blood pressure. In another analysis of two studies with use of sibutramine for 48 weeks Jordan et al. (2005) reported that sibutramine significantly reduced body weight but did not lead to a difference in systolic blood pressure after 48 weeks (Ϫ0.1 Ϯ 15.5 mm Hg for placebo versus Ϫ0.2 Ϯ 1.52 mm Hg for the sibutramine group). However, the change in diastolic blood pressure was statistically significant with a small rise of ϩ0.3 Ϯ 9.5 mm Hg in the sibutramine group and a decrease of Ϫ0.8 Ϯ 9.2 mm Hg in the placebo group (P ϭ 0.049).
iii. Sibutramine plus behavioral weight loss. Sibutramine has been studied as part of a behavioral weight-loss program in two reports (Wadden et al., 2005) . With sibutramine alone, the weight loss over 12 months was ϳ5.0 Ϯ 7.4 kg (5%). Behavior modification alone produced a weight loss of 6.7 Ϯ 7.9 kg. Adding a brief behavioral therapy session to a group that also received sibutramine produced a slightly larger weight loss of 7.5 Ϯ 8.0 kg. When the intensive lifestyle intervention was combined with sibutramine, the weight loss increased to 12.1 Ϯ 9.8 kg. When a structured meal plan was added to the medication and behavioral modification in one of these studies (Wadden et al., 2005) , the weight loss increased further to 15 kg (Wadden et al., 2001) . Completing the food intake records was a strong predictor of success (Wadden et al., 2005) . Those in the combined therapy group receiving an intensive lifestyle program and sibutramine who were in the highest third for record keeping lost 18.1 Ϯ 9.8 kg compared with 7.7 Ϯ 7.5 kg in the lowest third for record-keeping (Fig. 8) .
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iv. Studies in children.
Sibutramine has also been used in children and adolescents (Berkowitz et al., 2003 (Berkowitz et al., , 2006 Godoy-Matos et al., 2005) . In a single center, 85 adolescents aged 13 to 17 years with a BMI of 32 to 44 kg/m 2 were randomized to treatment for 6 months with placebo or sibutramine. Weight loss in the drug-treated group was 7.8 kg, for an 8.5% reduction in BMI, compared with 3.2 kg in the placebo group, for a 4.0% reduction in BMI. When the placebo group was switched to sibutramine after 6 months, there was an additional significant weight loss in this group. In a 12-month, multicenter, randomized, placebo-controlled trial, 498 adolescents aged 12 to 16 were treated with sibutramine or placebo (Berkowitz et al., 2006) . The dose of sibutramine was 10 mg/day for 6 months and then increased to 15 mg/day in those who had not lost Ͼ10% of their baseline BMI. After 12 months, the mean absolute change in BMI was Ϫ2.9 kg/m 2 (Ϫ8.2%) in the sibutramine group compared with Ϫ0.3 kg/m 2 (Ϫ0.8%) in the placebo group (P Ͻ 0.001). Triglycerides HDL cholesterol, and insulin sensitivity improved, and there was no significant difference in either systolic or diastolic blood pressure.
d. Meta-analysis of sibutramine studies. Several meta-analyses of sibutramine have been published (Haddock et al., 2002; Avenell et al., 2004; Li et al., 2005) . By pooling four studies Haddock et al. (2002) estimated the weight loss in patients treated with sibutramine as Ϫ5.3 kg (range 4.0 -7.3 kg) compared with Ϫ1.8 kg (range 0.8 -3.3 kg) for the placebo-treated groups. In the meta-analysis of Li et al. (2005) , the overall mean difference after 12 months of therapy in five studies was Ϫ4.45 kg (95% CI Ϫ5.29 to Ϫ3.62 kg) ( Table 7) .
In the meta-analysis by Avenell et al. (2004) , the overall placebo-subtracted effect of sibutramine at 12 months was Ϫ4.12 kg (95% CI Ϫ4.97 to Ϫ3.26 kg). Table  8 shows a summary for each of the trials that had data for sibutramine out to 12 months . After an additional interval in the weight maintenance studies, the data showed a loss at 15 months of Ϫ3.70 kg (95% CI Ϫ5.71 to Ϫ1.69 kg) (Apfelbaum et al., 1999) and at 18 months of Ϫ3.40 kg (95% CI Ϫ4.45 to Ϫ2.35 kg) (James et al., 2000) .
e. Combining sibutramine and orlistat. Because sibutramine works on noradrenergic and serotonergic reuptake mechanisms in the brain and orlistat works peripherally to reduce triglyceride digestion in the GI tract, their mechanisms of action do not overlap and combining them might provide additive weight loss (Wadden et al., 2000) . To test this possibility, researchers randomly assigned patients to orlistat or placebo after 1 year of treatment with sibutramine (Wadden et al., 2000) . During the additional 4 months of treatment, the two groups lost no significant amount of weight and adding orlistat had no detectable effect.
In an open-label randomized 12-week study, 86 overweight patients were assigned to treatment with 120 mg of orlistat three times a day, to treatment with 10 mg/day of sibutramine, the combination of orlistat and sibutramine, or to a diet group. During the 12 weeks, sibutramine produced more weight loss than orlistat alone. In another study, 150 obese subjects were randomized to 850 mg of metformin b.i.d., 120 mg of orlistat t.i.d., or 10 mg of sibutramine b.i.d. treatment for 6 months. The BMI decreased by Ϫ9.1, Ϫ9.9, and Ϫ13.6%, respectively. Weight loss was greater in the sibutramine group than in either the metformin or orlistat groups (P Ͻ 0.001) (Gokcel et al., 2002) . A third study, also of 6 months' duration, randomized 89 obese women to orlistat, sibutramine, or the combination and showed weight losses of 5.5, 10.1, and 10.8 kg, respectively. The combination was superior to orlistat but not to sibutramine alone (Sari et al., 2004) . A fourth study randomized 86 obese subjects to 10 mg/day of sibutramine, 360 mg/day of orlistat, the combination, or diet alone. In this study, the combination group lost more weight than the diet alone or orlistat groups, but the amount lost was similar to that for sibutramine alone . Thus, adding orlistat to sibutramine did not significantly enhance weight loss, confirming the observations of Wadden et al. (2000) and Kaya et al. (2004) . f. Dosage and safety considerations. Sibutramine is available in 5-, 10-, and 15-mg doses; 10 mg per day as a single dose is the recommended starting level, with titration up or down, depending on response. Doses higher than 15 mg/day are not recommended. Of the patients who lost 2 kg (4 lb) in the first 4 weeks of treatment, 60% achieved a weight loss of Ͼ5%, compared with Ͻ10% of those who did not lose 2 kg (4 lb) in 4 weeks. Combining data from the 11 studies on sibutramine showed a reduction in triglyceride, total cholesterol, and LDL cholesterol levels and an increase in HDL cholesterol levels that were related to the magnitude of the weight loss.
Rimonabant. a. Mechanism of action.
There are two cannabinoid receptors CB-1 (470 amino acids in length) and CB-2 (360 amino acids in length). The CB-1 receptor has almost all the amino acids that comprise the CB-2 receptor with additional amino acids at both ends. CB-1 receptors are distributed through the brain in the areas related to feeding, on fat cells, in the gastrointestinal tract. The CB-2 receptors are primarily on immune cells.
Marijuana and tetrahydrocannabinol, which stimulate the CB-1 receptor, both increase high fat and high sweet food intake. There are two well-characterized endogenous endocannabinoids called anandamide and 2-arachidonylglycerol. When injected into the brain, they also increase food intake. In human beings, fasting increases the levels of these endocannabanoids. The rewarding properties of cannabinoid agonists are mediated through the mesolimbic dopaminergic system.
Rimonabant is a specific antagonist of the CB-1 receptor. It inhibits intake of sweet foods by marmosets and reduces intake of high-fat foods in rats. Intake of standard rat chow is not affected by rimonabant. In addition to inhibiting the intake of highly palatable foods, pairfeeding experiments in diet-induced obese rats showed that the rimonabant-treated animals lost 21% of their body weight compared with 14% in the pair-fed controls. This suggests, at least in rodents, that rimonabant increases energy expenditure in addition to reducing food intake. CB-1 knockout mice are lean and resistant to diet-induced weight gain. CB-1 receptors are up-regulated on adipocytes in diet-induced obese mice, and rimonabant increases adiponectin, a fat cell hormone associated with insulin sensitivity (Bensaid et al., 2003; Kirkham, 2005; Juan-Pico et al., 2006; Pagotto et al., 2006 and was intended to be conducted in Europe, but slow recruitment led to inclusion of 276 subjects from the United States. This was a 2-year trial with 1-year results reported in this article. A total of 1507 patients with a BMI Ͼ30 kg/m 2 without comorbidities or a BMI Ͼ27 kg/m 2 with hypertension or dyslipidemia were stratified on whether they lost Ͼ or Ͻ2 kg during the run-in and then were randomized in a ratio of 1:2:2 to receive placebo, 5 mg/day of rimonabant, or 20 mg/day of rimonabant. The energy content of the diet was calculated by subtracting 600 kcal/day from the energy requirements calculated from the Harris-Benedict equation. The trial consisted of a 4-week run-in period followed by 52 weeks of drug treatment. Of those who started, 61% (920) completed the 1st year. Weight loss was Ϫ2% in the placebo group and Ϫ8.5% in the 20-mg rimonabant group. Baseline weight was between 98.5 kg (placebo group) and 102.0 kg (for the rimonabant 20-mg/day dose). During the run-in, there was a mean Ϫ1.9-kg weight loss. From baseline at the end of the run-in those in placebo the group who completed the trial lost an additional Ϫ2.3 kg, the low-dose rimonabant group (5 mg/day) lost Ϫ3.6 kg, and the high-dose group (20 mg/day) lost Ϫ8.6 kg. On an intent-to-treat basis these numbers were a weight loss of Ϫ1.8 kg for the placebo group, Ϫ3.4 kg for the 5-mg/day group, and Ϫ6.6 kg for the 20-mg/day group. Expressing the data as a responder analysis, the authors reported that 30.5% of the placebo group lost Ն5%, compared with 44.2% for the 5-mg/day and 67.4% for the 20-mg/day dose of rimonabant. When a weight loss of Ն10% was considered, the numbers were 12.4% for the placebo group, 15.3% for the 5 mg/day dose of rimonabant group, and 39% for the 20-mg/day dose group. Waist circumference was also reduced by treatment. With the intentto-treat analysis, waist declined 2.4 cm in the placebo group, 3.9 cm in the 5-mg/day dose group, and 6.5 cm in the 20-mg/day dose group. Triglycerides were reduced by 6.8% in the 20-mg/day group compared with a rise of 8.3% in the placebo group. HDL cholesterol increased by 22.3% compared with 13.4% in the placebo group. These changes in metabolic parameters were reflected in a change in the prevalence of the metabolic syndrome. Among those in the placebo group who completed the study, there was a 33.9% reduction in the prevalence of the metabolic syndrome, compared with 34.8% in the 5-mg/day rimonabant dose group and 64.8% in the 20-mg/day dose group. In the 20-mg/day group the LDL particle size increased, adiponectin increased, glucose decreased, insulin decreased, C-reactive protein decreased, and the metabolic syndrome prevalence was cut in half.
There was no significant change in blood pressure or pulse among the groups. Discontinuation for adverse events was similar, but the reasons were different. Among placebo-treated patients, it was for lack of weight loss. With the higher dose of rimonabant (20 mg/day) depressed mood disorders, nausea, vomiting, diarrhea, headache, dizziness, and anxiety were all more common than in the placebo group. The Hospital Anxiety and Depression scale scores were not significantly different among treatment groups.
Slightly more patients withdrew for drug-related adverse events in the 5-mg/day dose group and even more with the 20-mg/day dose relative to those receiving placebo. The major reasons for withdrawal were psychiatric, nervous system, and gastrointestinal track symptoms. The complaints, which occurred with Ͼ5% frequency in the drug-treated patients, included upper respiratory tract infection, nasopharyngitis, nausea, influenza, diarrhea, arthralgia, anxiety, insomnia, viral gastroenteritis, dizziness, depressed mood, and fatigue in the 20-mg/day dose group (Pi-Sunyer et al., 2006) .
The second study was in dyslipidemic patients and was called the Rimonabant in Obesity-Lipids (RIO-Lipids) study (Despres et al., 2005) . This was a 12-month randomized, double-blind, placebo-controlled trial of rimonabant at 5-and 20-mg/day doses versus placebo in overweight subjects eating a 600-kcal/day deficit diet. It was conducted at 67 sites in eight countries. As a lipids trial, the inclusion criteria were a BMI of 27 to 40 kg/m 2 , elevated fasting triglycerides (150 -700 mg/dl), ratio of cholesterol to HDL-cholesterol Ͼ5 in men and Ͼ4.5 in women, and no more than 5-kg variation in body weight in the previous 3 months. Subjects were stratified at the run-in by triglycerides Ͻ or Ͼ400 mg/dl and at the end of run-in by a weight loss of Ͼ or Ͻ2 kg. Randomization was on a 1:1:1 basis of placebo, 5 mg/day of rimonabant, and 20 mg/day of rimonabant. After the end of the 4-week run-in participants, were randomized and treated for 12 months; the dropout rate was ϳ40% by the end of 12 months. Weight losses in this trial were almost identical to those in the Rio-Europe trial. After an ϳ2-kg weight loss during the run-in, the patients in the placebo group who completed the trial lost an additional Ϫ2.3 kg, compared with Ϫ4.2 kg in the 5-mg/day rimonabant dose group and Ϫ8.8 kg in the 20-mg/day dose group. Waist circumference also showed a dose-dependent reduction of Ϫ3.4 cm in the placebo group, Ϫ4.9 cm in the 5-mg/day dose group, and Ϫ9.1 cm in the 20-mg/day dose group.
A number of other metabolic parameters also responded to the drug or weight loss. These included a decrease in triglycerides, an increase in HDL cholesterol, a decrease in peak size of LDL cholesterol particles, an increase in adiponectin, a decline in fasting insulin, a fall in leptin and a decrease in C-reactive protein. Several liver enzymes fell with treatment, suggesting improvement in nonalcoholic steatosis. Blood pressure decreased significantly in RIO-Lipids in contrast with RIO-Europe. As might be expected from these metabolic changes, the prevalence of the metabolic syndrome in those who met the Adult Treatment Panel III criteria at randomization fell to 25.8% in the 20-mg/day group, to 40.0% in the 5-mg/day group, and to 41.0% in the placebo group.
The third randomized, double-blind, placebo-controlled study, called RIO-North America, was also a 2-year study in which randomized 3045 overweight subjects with a BMI Ͼ30 kg/m 2 or with a BMI Ͼ27 kg/m 2 with treated or untreated hypertension or dyslipidemia and without diabetes to placebo, 5 mg/day of rimonabant, or 20 mg/day of rimonabant. Participants were instructed on a 600-kcal/day deficit diet. Randomization and baseline occurred after a 4 week run-in period in which subjects lost an average of Ϫ1.9 kg. They were thus stratified by whether they lost Ͼ or Ͻ2 kg during the run-in. At 1 year, half of the patients in each drug group were switched to placebo on the basis of their initial randomization. The trial was conducted at 64 American and 8 Canadian centers. At 1 year, completion rates were 51 to 55% for the three arms. During the 1st year, weight loss was Ϫ2.8 kg in the placebo group and Ϫ8.6 kg in the 20-mg/day rimonabant group (Fig. 9) . Weight loss declined steadily until week 36, after which it plateaued. For the 2nd year, those individuals who were switched from rimonabant to placebo regained weight at almost the mirror image of the rate at which they lost it during the 1st year. At the end of the study they were still slightly lighter, but no different from the group treated with placebo for the full 2 years. Waist circumference decreased, and the percentage with the metabolic syndrome decreased from 34.8 to 21.2% in the 20-mg/day group compared with a change from 31.7 to 29.2% in the placebo group. HDL cholesterol rose more in the rimonabant group treated with 20 mg/day than placebo, and triglycerides fell more in the participants receiving the higher dose of rimonabant. Patients with depression were not included in this study. Adverse events leading to discontinuation of the study were DRUG TREATMENT OF OBESITY higher in the rimonabant-treated than in the placebotreated participants. However, the profile and effectiveness of this agent seem very promising for treatment of obesity and the physical and laboratory findings that make up the metabolic syndrome. c. Studies in special populations. i. Diabetic patients. The fourth study, RIO-Diabetes, was conducted in type 2 diabetic patients. In it, 1045 diabetic subjects treated with diet, metformin, or sulfonylurea drugs at 151 centers in 11 countries were randomized to treatment over 1 year with placebo or rimonabant at 5 or 20 mg/day. Weight loss in the placebo group was Ϫ1.4 kg, compared with Ϫ2.3 kg in the 5-mg/ day group and Ϫ5.3 kg in the 20-mg/day group. Triglycerides and blood pressure declined more in the subjects treated with 20-mg/day rimonabant. Of those who completed the trial, 55.9% lost Ͼ5% of body weight during treatment with 20-mg/day rimonabant compared with 19.5% in the placebo-treated group (Scheen et al., 2006) .
ii. Prevention of weight gain after cessation of smoking. Studies with rimonabant suggest that it can slow or prevent the weight gain of individuals who have quit smoking.
d. Safety considerations. Because this drug "dampens" the feedback systems for pleasurable responses, there is concern about its behavioral effects. To quote from the most recently published article (Scheen et al., 2006) , "A slightly greater proportion of patients in the rimonabant treatment groups experienced adverse events than did those in the placebo group." The events occurring at a frequency of Ͼ5% in the rimonabant group included nausea, diarrhea, vomiting, dizziness, hypoglycemia, fatigue, and anxiety, all of which were generally mild or moderate. Discontinuation for adverse events was also more common in the higher-dose rimonabant group. The most common events for discontinuation were depressed mood disorders, nausea, and dizziness. . They were originally thought to "release" norepinephrine from vesicular stores, but more recent data suggest that they act primarily to inhibit reuptake of norepinephrine and dopamine at nerve endings.
b. Clinical studies. Most of the data on phentermine, diethylpropion, benzphetamine, and phendimetrazine come from short-term trials . One of the longest of these clinical trials lasted 36 weeks and compared placebo treatment with continuous phentermine or intermittent phentermine (Munro et al., 1968) . Both continuous and intermittent phentermine therapy produced more weight loss than placebo. In the drug-free periods, the patients treated intermittently slowed their weight loss, only to lose weight more rapidly when the drug was reinstituted.
In their analysis of pharmacotherapy for treatment of the overweight patient, Haddock et al. (2002) compiled data on both phentermine and diethylpropion. They found that in six studies, phentermine produced a mean weight loss of Ϫ6.3 kg (range Ϫ3.6 to Ϫ8.8 kg) compared with a placebo-induced weight loss of Ϫ2.8 kg (range Ϫ1.5 to Ϫ 5.2 kg). For diethylpropion, the mean weight loss in nine studies was Ϫ6.5 kg (range Ϫ1.9 to Ϫ 13.1 kg), and for the placebo group it was Ϫ3.5 kg (range Ϫ0.4 to Ϫ 10.5 kg). Similar data for benzphetamine are Ϫ4.03 kg (range Ϫ1.6 to Ϫ 7.3 kg) and for placebo Ϫ0.73 kg (range Ϫ1.3 to Ϫ 2.0 kg).
Phentermine and diethylpropion are classified by the U.S. Drug Enforcement Agency as schedule IV drugs; benzphetamine and phendimetrazine are schedule III drugs. This regulatory classification indicates the U.S. Government's belief that they have the potential for abuse, although this potential seems to be very low. Phentermine and diethylpropion are approved for only a "few weeks," which usually is interpreted as up to 12 weeks. Weight loss with phentermine and diethylpropion persists for the duration of treatment, suggesting that tolerance does not develop to these drugs. If tolerance were to develop, the drugs would be expected to lose their effectiveness, and patients would require increased amounts of the drug to maintain weight loss. This does not occur. 
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IV. Antidepressant and Antiepileptic Drugs That Produce Weight Loss but Are Not Approved by the U.S. Food and Drug Administration for Weight Loss
A. Fluoxetine and Sertraline
Mechanism of Action.
Fluoxetine and sertraline are both selective serotonin reuptake inhibitors that block the transporters that remove serotonin from the neuronal cleft into the presynaptic space for metabolism by monoamine oxidase or storage in granules. They also reduce food intake. In a 2-week placebo-controlled trial, fluoxetine at a dose of 60 mg/day produced a 27% decrease in food intake (Lawton et al., 1995) .
2. Clinical Studies. Both fluoxetine and sertraline are approved by the FDA for treatment of depression. In clinical trials with depressed patients lasting 8 to 16 weeks, sertraline gave an average weight loss of Ϫ0.45 to Ϫ0.91 kg. Fluoxetine at a dose of 60 mg/day (three times the usual dose for treatment of depression) was evaluated in clinical trials for the treatment of overweight patients by Eli Lilly & Co. A meta-analysis of six studies showed a wide range of results with a mean weight loss in one study of Ϫ14.5 kg and a weight gain of ϩ0.40 kg in another (Li et al., 2005) . In the meta-analysis by Avenell et al. (2004) , the weight loss at 12 months was Ϫ0.33 kg (95% CI Ϫ1.49 to 0.82 kg). Goldstein et al. (1995) reviewed the trials with fluoxetine that included one 36-week trial in type 2 diabetic subjects, a 52-week trial in subjects with uncomplicated overweight, and two 60-week trials in subjects with dyslipidemia, diabetes, or both. A total of 1441 subjects were randomized to fluoxetine (719) or placebo (722); 522 subjects receiving fluoxetine and 504 subjects receiving placebo completed 6 months of treatment. Weight loss in the placebo and fluoxetine groups at 6 months and 1 year were Ϫ2.2 and Ϫ4.8 kg and Ϫ1.8 and Ϫ2.4 kg, respectively. The recovery of 50% of the lost weight during the second 6 months of treatment with fluoxetine makes it inappropriate for the long-term treatment of overweight, which requires chronic treatment. Fluoxetine and sertraline, although not good antioverweight drugs, may be preferred in the depressed obese patient over some of the tricyclic antidepressants that are associated with significant weight gain (Fig. 10) .
B. Bupropion
Mechanism of Action.
Bupropion is a norepinephrine and dopamine reuptake inhibitor that is approved for the treatment of depression and for smoking cessation.
Clinical Studies for Weight Loss.
One clinical use for bupropion has been to prevent weight gain after cessation of smoking. It was thus a potential drug for treatment of overweight patients. In one clinical trial, 50 overweight subjects were randomized to bupropion or placebo for 8 weeks with a blinded extension for responders to 24 weeks. The dose of bupropion was increased to a maximum of 200 mg twice daily in conjunction with a calorie-restricted diet. At 8 weeks, 18 subjects in the bupropion group lost Ϫ6.2 Ϯ 3.1% of body weight compared with Ϫ1.6 Ϯ 2.9% for the 13 subjects in the placebo group (P Ͻ 0.0001). After 24 weeks, the 14 responders to bupropion lost Ϫ12.9 Ϯ 5.6% of initial body weight, of which 75% was fat as determined by dual energy X-ray absorptiometry (Gadde et al., 2001) .
Two multicenter clinical trials, one in obese subjects with depressive symptoms and one in uncomplicated overweight patients, followed this study. In the study of overweight patients with depressive symptom ratings of 10 to 30 on a Beck Depression Inventory, 213 patients were randomized to 400 mg of bupropion per day and 209 subjects to placebo for 24 weeks. The 121 subjects in the bupropion group who completed the trial lost Ϫ6.0 Ϯ 0.5% of initial body weight compared with Ϫ2.8 Ϯ 0.5% in the 108 subjects in the placebo group (P Ͻ 0.0001) (Jain et al., 2002) . The study in uncomplicated overweight subjects randomized 327 subjects to 300 mg/day of bupropion, 400 mg/day of bupropion, or placebo in equal proportions. At 24 weeks, 69% of those randomized remained in the study and the percent losses of initial body weight were Ϫ5 Ϯ 1, Ϫ7.2 Ϯ 1, and Ϫ10.1 Ϯ 1% for the placebo, 300 mg/day of bupropion, and 400 mg/day of bupropion groups, respectively (P Ͻ 0.0001). The placebo group was randomized to the 300-or 400-mg/day group at 24 weeks, and the trial was extended to week 48. By the end of the trial, the dropout rate was 41%, and the weight loss in the 300-mg/day bupropion and 400-mg/day bupropion groups was Ϫ6.2 Ϯ 1.25% and Ϫ7.2 Ϯ 1.5% of initial body weight, respectively (Anderson et al., 2002) . Thus, it seems that nondepressed subjects may respond to bupropion with weight loss to a greater extent than those with depressive symptoms (Fig. 11) . Because bupropion is at the end of its FIG. 10 . Effect on body weight of fluoxetine from pooled data of randomized, placebo-controlled clinical trials. Redrawn from Goldstein et al. (1995) .
DRUG TREATMENT OF OBESITY 167 patent life, it is not being developed for obesity, but similar drugs in this class would be obvious candidates.
C. Topiramate
Mechanism of Action.
Topiramate is a neurotherapeutic agent that is approved for treatment of selected seizure disorders. It is a weak carbonic anhydrase inhibitor, exhibiting selectivity for carbonic anhydrase isoforms II and IV. Topiramate also modulates the effects at receptors for the GABA-A receptor and the ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/ kainate subtype of the glutamate receptor. This drug also exhibits state-dependent blockade of voltage-dependent Na ϩ or Ca 2ϩ channels. These mechanisms are believed to contribute to its antiepileptic properties. The modulation of GABA receptors may provide one potential mechanism to reduce food intake, although other mechanisms, yet to be described, may be more important in defining its effects on body weight (Astrup and Toubro, 2004) . The final words on the mechanism(s) by which topiramate reduces food intake and body weight are yet to be published.
Clinical Studies for Weight Loss.
Topiramate is an antiepileptic drug that was discovered to give weight loss in the clinical trials for epilepsy. Weight losses of Ϫ3.9% of initial weight were seen at 3 months and losses of Ϫ7.3% of initial weight were seen at 1 year (BenMenachem et al., 2003) . Bray et al. (2003) reported a 6-month, placebo-controlled, dose-ranging study of 385 obese subjects who were randomized to placebo or topiramate at 64, 96, 192, or 384 mg/day. These doses were gradually reached by a tapering increase and were reduced in a similar manner at the end of the trial. Weight loss from baseline to 24 weeks was Ϫ2.6, Ϫ5, Ϫ4.8, Ϫ6.3, and Ϫ6.3% in the placebo, 64-, 96-, 192-, and 384-mg/day groups, respectively. The most frequent adverse events were paresthesias, somnolence and difficulty with concentration, memory, and attention. This trial was followed by two multicenter trials. The first trial randomized 1289 obese subjects to topiramate 89, 192, or 256 mg/day. This trial was terminated early because of the sponsor's decision to pursue a time-release form of the drug. The 854 subjects who completed 1 year of the trial before it was terminated lost Ϫ1.7, Ϫ7, Ϫ9.1, and Ϫ9.7% of their initial body weight in the placebo, 89-, 192-, and 256-mg/day groups, respectively. Subjects in the topiramate groups had significant improvement in blood pressure and glucose tolerance (Wilding et al., 2004) . The second trial enrolled 701 subjects who were treated with a very low-calorie diet to induce an 8% loss of initial body weight. The 560 subjects who achieved an 8% weight loss were randomized to 96 or 192 mg/day of topiramate or placebo. The sponsor also terminated this study early. At the time of termination, 293 subjects had completed 44 weeks. The topiramate groups lost 15.4 and 16.5% of their baseline weight whereas the placebo group lost 8.9% . Although topiramate is still available as an antiepileptic drug, the development program to obtain an indication for overweight was terminated by the sponsor because of the associated adverse events (Fig. 12) .
Special Situations.
Topiramate has also been evaluated in the treatment of binge-eating disorder. Thirteen women with binge-eating disorder were treated in an open-label study using a mean dose of 492 mg/day of topiramate. The binge-eating disorder symptoms improved, and weight loss was observed (Shapira et al., 2000) . This open-label study was followed by a randomized, controlled trial of 14 weeks in subjects with binge-eating disorder. Sixty-one subjects were randomized to 25 to 600 mg/day of topiramate or placebo in a 1:1 ratio. The topiramate group had improvement in binge eating symptoms and lost Ϫ5.9 kg at an average topiramate dose of 212 mg/day (McElroy et al., 2003) . The 35 subjects who completed this trial were given the opportunity to participate in an open-label extension. The topiramate-treated subjects continued to maintain improvement in binge-eating symptoms and weight (McElroy et al., 2004b) . 
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Topiramate has also been used to treat patients with the Prader-Willi syndrome. Three subjects with PraderWilli syndrome were treated with topiramate and had a reduction in the self-injurious behavior that is associated with this uncommon genetic disease (Shapira et al., 2002) . A second study in seven additional subjects confirmed these findings (Smathers et al., 2003) . A third study evaluated appetite, food intake, and weight. Although the self-injurious behavior improved, there was no effect on these other parameters (Shapira et al., 2004) . Topiramate was also used to treat two subjects with nocturnal eating syndrome and two subjects with sleep-related eating disorder. There was an improvement in all subjects and a Ϫ11-kg weight loss over 8.5 months with an average topiramate dose of 218 mg/day (Winkelman, 2003) .
D. Zonisamide
Mechanism of Action.
Zonisamide is an antiepileptic drug that has serotonergic and dopaminergic activity in addition to inhibiting sodium and calcium channels. The mechanism by which it lowers body weight has not been clarified.
Clinical Studies for Weight Loss.
Weight loss was noted in the clinical trials for the treatment of epilepsy, again suggesting a potential agent for weight loss. Gadde et al. (2003) tested this possibility by performing a 16-week randomized, controlled trial in 60 obese subjects. Subjects were placed on a calorie-restricted diet and randomized to zonisamide or placebo (Fig. 13) . The zonisamide was started at 100 mg/day and increased to 400 mg/day. At 12 weeks, the dose of zonisamide for those subjects who had not lost 5% of initial body weight was increased to 600 mg/day. The zonisamide group lost Ϫ6.6% of initial body weight at 16 weeks compared with Ϫ1% in the placebo group. Thirty-seven subjects completing the 16-week trial elected to continue to week 32. Of these, 20 were in the zonisamide group and 17 were in the placebo group. At the end of 32 weeks, the 19 subjects who remained in the zonisamide group lost Ϫ9.6% of their initial body weight compared with Ϫ1.6% for the 17 subjects in the placebo group. McElroy et al. (2004a) evaluated zonisamide in an open-label prospective trial in subjects with binge-eating disorder. Fifteen subjects were treated with doses of 100 to 600 mg/day for 12 weeks. The eight subjects who completed the trial had an average dose of 513 mg/day, experienced an improvement in their binge-eating symptoms and lost a significant amount of weight.
E. Lamotrigine
Mechanism of Action.
Lamotrigine is an antiepileptic drug that does not produce weight gain (Devinsky et al., 2000) .
Clinical Studies.
A recent double-blind, randomized, placebo-controlled trial examined the effects of placebo versus lamotrigine escalated from 25 to 200 mg/day on weight loss in a 26-week trial with 40 healthy overweight (BMI 30-40 kg/m 2 ) adults Ͼ18 years of age. At the end of the trial body weight was marginally lower (P ϭ 0.062) in the lamotrigine-treated group (Ϫ6.4 kg) than in the placebo-treated group (Ϫ1.2 kg) (Merideth, 2006) .
V. Drugs Approved by the U.S. Food and Drug Administration for Uses Other Than Overweight
A. Metformin 
Mechanism of Action.
Metformin is a biguanide that is approved for the treatment of diabetes mellitus, a disease that is exacerbated by overweight and weight gain. This drug reduces hepatic glucose production, decreases intestinal absorption from the gastrointestinal tract, and enhances insulin sensitivity.
Clinical Studies.
In clinical trials in which metformin was compared with sulfonylureas, it produced weight loss . In one French trial, Biguanides and Prevention of Risks in Obesity (BIGPRO), metformin was compared with placebo in a 1-year multicenter study in 324 middle-aged subjects with upper body adiposity and the insulin resistance syndrome (metabolic syndrome). The subjects receiving metformin lost significantly more weight (1-2 kg) than the placebo group, and the conclusion of the study was that metformin may have a role in the primary prevention of type 2 diabetes (Fontbonne et al., 1996) . In a meta-analysis of three of these studies Avenell et al. (2004) reported a weighted mean weight loss at 12 months of Ϫ1.09 kg (95% CI Ϫ2.29 to 0.11 kg).
The best trial of metformin is the Diabetes Prevention Program study of individuals with impaired glucose tolerance. The main part of this study included three treatment arms to which participants were randomly assigned, if they were Ͼ25 years of age, had a BMI Ͼ24 kg/m 2 (except Asian-Americans who only needed a BMI Ն22 kg/m 2 ), and had impaired glucose tolerance. The three primary arms included lifestyle (n ϭ 1079 partic- DRUG TREATMENT OF OBESITY ipants), metformin (n ϭ 1073), and placebo (n ϭ 1082). During the follow-up averaging 3.2 years, the metformin-treated group lost 2.5% of their body weight (P Ͻ 0.001, compared with placebo), and the conversion from impaired glucose tolerance to diabetes was reduced by 30% compared with placebo (Fig. 14) . In the DPP trial, metformin was more effective in reducing the development of diabetes in the subgroup who were most overweight and in the younger members of the cohort (Knowler et al., 2002) .
Although metformin does not produce enough weight loss (5%) to qualify as a "weight-loss drug" according to the FDA criteria, it would seem to be a very useful choice for overweight individuals who have diabetes or are at high risk for diabetes. One area for use of metformin is treatment of women with the polycystic ovary syndrome in whom a modest weight loss may contribute to increased fertility and reduced insulin resistance (OrtegaGonzalez et al., 2005) .
Metformin (850 mg) b.i.d. and 120 mg of orlistat t.i.d. were compared with 10 mg of sibutramine daily in obese subjects over 6 months. BMI decreased by Ϫ9.1, Ϫ9.9, and Ϫ13.6%, respectively. Weight loss was greater in the sibutramine group than in either the metformin or orlistat groups (P Ͻ 0.001) (Gokcel et al., 2002) .
B. Pramlintide
Mechanism of Action.
Amylin is peptide found in the ␤-cell of the pancreas. It is secreted along with insulin, and circulates in the blood. Amylin is deficient in type I diabetes in which ␤-cells are immunologically destroyed. Pramlintide is a synthetic amylin analog with a prolonged biological half-life (Riddle and Drucker, 2006) .
Clinical Studies.
Pramlintide is approved by the FDA for the treatment of diabetes. Unlike insulin, sulfonylureas, and thiazolidinediones, pramlintide is associated with weight loss. In a study of 651 subjects with type 1 diabetes randomized to placebo or subcutaneous pramlintide 60 g three or four times a day along with an insulin injection, the hemoglobin A 1c decreased Ϫ0.29 to 0.34% and weight decreased Ϫ1.2 kg in the pramlintide group relative to placebo (Ratner et al., 2004) . Maggs et al. (2003) analyzed the data from two 1-year studies in insulin-treated type II diabetic subjects randomized to pramlintide 120 g twice a day or 150 g three times a day. Weight decreased by Ϫ2.6 kg and hemoglobin A 1c decreased Ϫ0.5%. When weight loss was then analyzed by ethnic group, African Americans lost Ϫ4 kg, Caucasians lost Ϫ2.4 kg, and Hispanics lost Ϫ2.3 kg, and the improvement in diabetes correlated with the weight loss, suggesting that pramlintide is effective in ethnic groups with the greatest burden from overweight. The most common adverse event was nausea, which was usually mild and confined to the first 4 weeks of therapy.
C. Exenatide
Mechanism of Action.
GLP-1 is derived from the processing of the preproglucagon peptide, which is secreted by L-cells in the terminal ileum in response to a meal. Increased GLP-1 inhibits glucagon secretion, stimulates insulin secretion, stimulates gluconeogenesis, and delays gastric emptying (Patriti et al., 2004) . It has been postulated to be responsible for the superior weight loss and superior improvement in diabetes seen after gastric bypass surgery for overweight Small and Bloom, 2004) . GLP-1 is rapidly degraded by dipeptidyl peptidase-4, an enzyme that is elevated in the obese. Bypass operations for overweight increase levels of GLP-1, but do not change the levels of dipeptidyl pepidase-4 (Lugari et al., 2004; Riddle and Drucker, 2006) .
Exenatide (exendin-4) is a 39-amino acid peptide that is produced in the salivary gland of the Gila monster lizard. It has 53% homology with GLP-1, but it has a much longer half-life. Exenatide decreases food intake and body weight gain in Zucker rats while lowering hemoglobin A 1c (Szayna et al., 2000) . It also increases ␤-cell mass to a greater extent than would be expected for the degree of insulin resistance (Gedulin et al., 2005) . Exendin-4 induces satiety and weight loss in Zucker rats with peripheral administration and crosses the bloodbrain barrier to act in the central nervous system (Rodriquez de Fonseca et al., 2000; Kastin and Akerstrom, 2003) .
Clinical Studies with Weight Loss as a Component.
Exenatide has been approved by the U.S. Food and Drug Administration for treatment of type 2 diabetic patients whose diabetes is inadequately controlled with either metformin or sulfonylureas. In humans, exenatide reduces fasting and postprandial glucose levels, slows gastric emptying, and decreases food intake by 19% (Edwards et al., 2001) . The side effects of exenatide in humans are headache, nausea, and vomiting that are lessened by gradual dose escalation . Several clinical trials of 30 weeks' duration using exenatide at 10 g s. 
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BRAY AND GREENWAY et al., 2005) . In one trial with 377 type 2 diabetic subjects in whom maximal sulfonylurea therapy was failing, exenatide produced a 0.74% greater fall in hemoglobin A 1c than placebo. Fasting glucose also decreased, and there was a progressive weight loss of 1.6 kg (Buse et al., 2004) . The interesting feature of this weight loss is that it occurred without lifestyle changes, diet, or exercise (Fig. 15) . Two of the 30-week exenatide trials contained an open-label extension to 82 weeks. Those completing the 82 weeks of exenatide treatment at 10 g twice a day lost 5.3 kg in the trial with 150 subjects and 4.4 kg in the trial with 334 subjects (Blonde et al., 2006; Ratner et al., 2006) . In a 26-week randomized, controlled trial, exenatide produced a 2.3-kg weight loss compared with a gain of 1.8 kg in the group receiving insulin glargine (Heine et al., 2005) . A long-acting release form of exenatide is being developed. A press release by Eli Lilly & Co. described a 3.8-kg weight loss in diabetic subjects treated with this formulation given weekly for 15 weeks.
D. Somatostatin
Mechanism of Action.
Somatostatin is a small peptide that is released in the GI tract and in the brain. It inhibits the release of most peptides, including insulin, glucagon, and growth hormone, among others.
Clinical Studies for Weight Loss.
Overweight due to hypothalamic injury has been associated with insulin hypersecretion (Bray and Gallagher, 1975) . Lustig et al. (1999) treated eight children with overweight due to hypothalamic damage with octreotide injections to decrease insulin hypersecretion. These children gained 6 kg in the 6 months before octreotide treatment and lost Ϫ4.8 kg in the 6 months of treatment with octreotide, an analog of somatostatin. The weight loss was correlated with a reduction in insulin secretion on a glucose tolerance test. This open-label trial was followed by a randomized, controlled trial of octreotide treatment in children with hypothalamic overweight. The subjects received octreotide 5 to 15 g/kg/day or placebo for 6 months. The children receiving octreotide gained 1.6 kg compared with 9.1 kg for those in the placebo group . This same group of investigators postulated that there might be a subset of obese subjects who were insulin hypersecretors and that these subjects would respond to treatment with octreotide by losing weight. After an oral glucose tolerance test in which glucose and insulin were measured, 44 subjects were treated with long-acting 40-mg/month octreotide for 6 months. These subjects lost weight, reduced food intake, and reduced carbohydrate intake. Weight loss was greatest in those with insulin hypersecretion, and the amount of weight loss was correlated with the reduction in insulin hypersecretion (Velasquez-Mieyer et al., 2003) . In a multicenter randomized, controlled trial, 172 obese subjects (144 women and 28 men) who had insulin hypersecretion during a glucose tolerance test at screening received long-acting octreotide in doses of 20, 40, or 60 mg/month or placebo for 6 months. The greatest weight loss was 3.5 to 3.8% of initial body weight in the two higher dose groups, an amount that was statistically significant, but not enough to meet the criteria for approval by the FDA (Lustig et al., 2006) .
Octreotide has been shown to decrease gastric emptying (Foxx-Orenstein et al., 2003) . Treatment of patients with the Prader-Willi syndrome who have elevated ghrelin levels does not cause weight loss, but ghrelin levels are normalized. The reason for the lack of weight loss was postulated to be the reduction of PYY, a satiating gastrointestinal hormone that was also decreased (Tan et al., 2004 ).
E. Atomoxetine
Mechanism of Action.
Atomoxetine is a central norepinephrine uptake inhibitor approved for the treatment of attention-deficit/hyperactivity disorder.
Clinical Study for Weight Loss.
Thirty obese women were randomized to atomoxetine increasing from 25 to 100 mg/day or placebo in a 12-week trial. The atomoxetine group lost 3.8 kg more weight than the placebo group, and the drug seemed to be well tolerated .
F. Growth Hormone and Growth Hormone Fragment
Mechanism of Action.
Growth hormone is a pituitary peptide that is essential for the adolescent growth spurt. Bioengineered growth hormone is widely used to treat short stature as well as growth hormone deficiency in adults (Hoffman et al., 2004) and has been used by athletes to build muscle, as one of its effects is to enhance protein accretion. Growth hormone has been consistently shown to increase body protein and to reduce total body fat and particularly visceral fat, making it a potential agent to treat the overweight patient. DRUG TREATMENT OF OBESITY nosed diabetes were randomly assigned to placebo or growth hormone injection along with dietary restriction in a double-blind study (Nam et al., 2001) . These authors found a greater decrease in visceral fat, an increase in lean body mass, and improved insulin sensitivity during this 12-week trial. In a 12-month randomized doubleblind, placebo-controlled clinical trial, 40 postmenopausal women were assigned to daily placebo injections or injections of growth hormone (0.67 mg/day). After 1 year Franco et al. (2005) reported that the women had significantly reduced abdominal and visceral adiposity, improved insulin sensitivity, and improved total and low-density lipoprotein cholesterol concentrations.
Clinical Studies on Body
A group working in Australia has identified a fragment of growth hormone that is lipolytic. This compound, called AOD9604, is a modified fragment of the amino acids from 177 to 191 in growth hormone. It is orally active and is said to bind to the fat cell, stimulating lipolysis and inhibiting reesterification without stimulating growth. A 12-week multicenter trial randomized 300 obese subjects to one of five daily doses (1, 5, 10, 20 , and 30 mg) of AOD9604 or placebo. The 1-mg dose was the most effective for weight loss. Subjects receiving the 1-mg dose lost Ϫ2.6 kg compared with Ϫ0.8 kg in the placebo group, and the rate of weight loss was constant throughout the trial (http://www.metabolic. com.au/files/T5SH4035T6/ASX_%20AOD9604_result-%20announcement.pdf). Phase III trials are evidently in the planning stages.
VI. Drugs with Clinical Data or in Clinical Studies
A. Leptin
Mechanism of Action.
Leptin is a cytokine that acts on the gp130 family of cytokine receptors in the hypothalamus to activate the Janus kinase signal transduction and translation system (JAK-STAT). The lack of leptin, a hormone derived primarily from the fat cell, causes massive overweight in animals and humans. Its replacement reverses the overweight associated with the deficiency state. The discovery of leptin generated hope that leptin would be an effective treatment for overweight.
2. Clinical Studies. Leptin at subcutaneous doses of 0 (vehicle), 0.01, 0.05, 0.1, and 0.3 mg/kg daily was tested in lean and obese humans of both sexes. Lean subjects were treated for 4 weeks and lost Ϫ0.4 to Ϫ1.9 kg. Obese subjects were treated for 24 weeks and a dose-response relationship for weight loss was seen with the 0.3-mg/kg group losing Ϫ7.1 kg (Heymsfield et al., 1999) . Pegylated leptin allows for weekly, rather than daily, injections. Although pegylated leptin at 20 and 60 mg/week in obese subjects over 8 to 12 weeks did not produce more weight loss than placebo, the pegylated leptin at 80 mg weekly combined with a very low-calorie diet for 46 days produced 2.8 kg more weight loss in 12 subjects randomized to leptin compared with the 10 subjects randomized to placebo (P Ͻ 0.03) (Hukshorn et al., 2003) .
Leptin has been found to ameliorate many of the symptoms of lipodystrophy. Nine female patients with lipodystrophy and serum leptin levels of Ͻ4 ng/ml were treated with recombinant methionyl human leptin for 4 months. Eight of the women had diabetes. During treatment with leptin, glycosylated hemoglobin decreased an average of 1.9% During the 4 months of therapy, triglyceride levels decreased by 60%. Liver volume was also reduced by an average of 28% and resting metabolic rate decreased significantly with therapy (Oral et al., 2002) . A reduction in body weight produced by eating a lowcalorie diet is associated with decreased 24-h energy expenditure and decreased leptin and thyroid hormone levels. When body weight was reduced by 10%, circulating triiodothyronine, thyroxine, and leptin concentrations were decreased. All of these endocrine changes were reversed by administration of "replacement" doses of recombinant human methionyl-leptin. Total energy expenditure increased in all subjects during treatment with leptin, indicating that decreased leptin may account for some aspects of the endocrine adaptations to weight loss (Rosenbaum et al., 2002) .
Leptin has been evaluated in combination with amylin in rodents with diet-induced obesity (Roth et al., 2006) . Leptin treatment gave a weight gain of 0.6% of body weight, amylin gave a weight loss of 3.4% of body weight, and the combination gave a weight loss of 7.1% body weight. In another pair-feeding experiment, the leptin-and amylin-treated rats lost 12% of body weight compared with only 6.9% in the pair-fed group, suggesting that both a reduction in food intake and an increase in metabolic rate are responsible for the weight loss. These findings suggest that amylin restores sensitivity to leptin. . Levels of NPY in the hypothalamus are temporally related to food intake and are elevated with energy depletion. Surprisingly, NPY knockout mice have no phenotype. NPY 5 receptor antagonists fall into two categories, those that reduce food intake and those that do not, but those that do seem to do so through a mechanism separate from the Y 5 receptor. Thus, one group concluded that Y 5 receptor antagonists do not seem promising as antioverweight agents (Levens and Della-Zuana, 2003) . In contrast, Y 1 receptor antagonists seem to have greater potential as antioverweight agents. A dihydropyridine neuropeptide Y 1 antagonist inhibited NPY-induced feeding in satiated rats (Poindexter et al., 2002) . Another Y 1 receptor antagonist J-104870, suppressed food intake when given orally to Zucker rats (Kanatani et al., 2001) .
Clinical Studies.
A study measuring NPY in obese humans casts doubt on the importance of the NPY antagonists in the treatment of overweight in humans. Obese women had lower NPY levels than lean women, and weight loss with a 400-kcal/day diet and adrenergic agonists (caffeine and ephedrine or caffeine, ephedrine, and yohimbine) did not change NPY levels at rest or after exercise (Zahorska-Markiewicz et al., 2001) .
Several clinical trials with a selective Y 5 receptor antagonist have been completed. The first was a 2-year randomized, placebo-controlled trial (Erondu et al., 2006) . It included two doses (Fig. 16) . The second trial was designed to test the effect of the antagonist on the prevention of weight gain induced by providing patients with a very low-calorie diet before randomization.
C. Serotonin 2C Receptor Agonists
Mechanism of Action.
Mice lacking the 5HT 2C receptor have increased food intake, because they take longer to be satiated. These mice also are resistant to fenfluramine, a serotonin agonist that causes weight loss. A human mutation of the 5HT 2C receptor has been identified that is associated with early-onset human obesity (Gibson et al., 2004; Nilsson, 2006) . The precursor of serotonin, 5-hydroxytryptophan, reduces food intake and body weight in clinical studies (Cangiano et al., 1992 ). Fenfluramine (Rogers and Blundell, 1979 (Foltin et al., 1996) and dexfenfluramine (Drent et al., 1995) , two drugs that act on the serotonin system, but were withdrawn from the market in 1997 because of cardiovascular side effects, also reduce food intake in human studies. meta-Chlorophenylpiperazine, a direct serotonin agonist, reduces food intake by 28% in women and 20% in men (Walsh et al., 1994) . Another serotonergic drug, sumatriptan, which acts on the 5-HT 1B/1D receptor, also reduced food intake in human subjects (Boeles et al., 1997) . Because of the robust effects of agonists toward the 5-HT 2C receptors in suppressing food intake, a number of new agents are now under development.
Only one of these, described below, has advanced to formal clinical trials 2. Clinical Studies. The results of a 12-week phase II dose-ranging study of lorcaserin (APD356) have been presented . A total of 459 male and female subjects with a BMI between 29 and 46 kg/m 2 with an average weight of 100 kg were enrolled in a randomized, double-blind, controlled trial comparing placebo against 10 and 15 mg given once daily and 10 mg given twice daily (20 mg/day). Over the 12 weeks of the trial, the placebo group gained ϩ0.32 kg (n ϭ 88 completers) compared with Ϫ1.8 kg in the 10-mg/day dose given once daily (n ϭ 86 completers), Ϫ2.6 kg in the 15-mg/day dose (n ϭ 82 completers), and Ϫ3.6 kg in the 10-mg-twice-daily dose (20 mg total) (n ϭ 77 completers). Side effects that were higher in the active treatment groups than the placebo group were headache, nausea, dizziness, vomiting, and dry mouth. No cardiac valvular changes were noted.
D.
Peptide YY 3-36 is a hormone produced by the L-cells in the gastrointestinal tract and is secreted in proportion to the caloric content of a meal. PYY 3-36 levels are lower after fasting and after a meal in overweight subjects compared with lean subjects. Development of a nasal spray formulation for PYY 3-36 has undergone a phase I clinical trial. Based on the review of this trial Merck severed its commercial relationship with Nastech Pharmaceutical Company on March 1, 2006 . Nastech, the developer of the nasal formulation, plans to continue developing this product.
2. Clinical Studies. Caloric intake at a lunch buffet was reduced by 30% in 12 obese subjects and by 29% in 12 lean subjects after 2 h of PYY 3-36 infused i.v. (Batterham et al., 2003) . These findings were confirmed by another group in normal weight subjects. Food intake was reduced by 35% during an (Degen et al., 2005) . Thrice daily nasal administration over 6 days was well tolerated and reduced caloric intake by ϳ30% while giving a 0.6-kg weight loss (Brandt et al., 2004 ).
E. Oxyntomodulin
Mechanism of Action.
Oxyntomodulin is a gastrointestinal peptide produced in the L-cells of the intestine and is released in response to food. Animals injected with oxyntomodulin have a reduction in body fat and food intake.
2. Clinical Studies. In a short 4-week clinical study, oxyntomodulin was reported to reduce food intake by 19.3% compared with a placebo infusion (Fig, 17) . In this 4-week randomized, double-blind, placebo-controlled trial, overweight volunteers injected themselves with oxyntomodulin or placebo s. 
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and adiponectin increased in the group receiving oxyntomodulin. Energy intake in the treated group decreased by 170 Ϯ 37 kcal (25 Ϯ 5%) at the beginning study meal and by 250 Ϯ 63 kcal (35 Ϯ 9%) at the final meal (Wynne et al., 2005) .
F. Pancreatic Lipase Inhibitor
Mechanism of Action.
Cetilistat is a lipase inhibitor. In a 5-day trial of cetilistat (ATL-962) in 90 normal volunteers housed on an inpatient unit, there was a 3-to 7-fold increase in fecal fat that was dose-dependent. Only 11% of subjects had more than one oily stool, leading to the suggestion that this lipase inhibitor may have fewer gastrointestinal adverse events than orlistat (Dunk et al., 2002) .
2. Clinical Studies. In a 12-week clinical trial, 612 obese diabetic subjects were randomized to 40, 80, or 120 mg of cetilistat, 120 mg of orlistat, or placebo given three times a day. Weight loss was Ϫ2.9, Ϫ3.9, Ϫ4.3, Ϫ3.8 kg, and Ϫ2.9 kg, respectively. The prevalence of gastrointestinal side effects was 11.6, 1.7 , and 4% in the orlistat, 120 mg of cetilistat, and placebo groups, respectively (Kopelman et al., 2006) .
G. Cholecystokinin
Cholecystokinin decreases food intake by causing subjects to stop eating sooner (Pi-Sunyer et al., 1982) . Although the relationship between cholecystokinin and satiety has been known for many years, development as a weight loss agent has been slow due to concerns about pancreatitis. Because the human pancreas has no cholecystokinin-A receptors, an orally active compound that is a selective agonist of the cholecystokinin-A receptor has been evaluated in clinical trials, but GlaxoSmithKline issued a press release in 2005 announcing discontinuation of their program in this area.
H. Combination of Bupropion and Naltrexone (Contrave)
The combination of naltrexone and bupropion (Contrave) is being developed for the treatment of obesity. Naltrexone is approved for the treatment of alcoholism. Naltrexone does not give significant weight loss alone, but by inhibiting a opioid receptor on the POMC neurons, it releases these neurons from opioid inhibition, augmenting POMC release and the weight loss effect of bupropion. A proof of concept trial with 50 mg/day of naltrexone and 300 mg of bupropion was reported in abstract form (Greenway et al., 2006a) . This 6-month study in 200 subjects gave initial body weight losses of Ϫ3.8, Ϫ2.2, Ϫ0.9, and Ϫ6.6% in the bupropion, naltrexone, placebo, and bupropion-naltrexone groups, respectively (P Ͻ 0.02, P Ͻ 0.001, and P Ͻ 0.001, compared with bupropion-naltrexone). Nausea, the major adverse event (40%), was driven by naltrexone and led to discontinuations in 12% of participants. Dose modification may increase efficacy and improve tolerability of this combination.
I. Combination of Bupropion and Zonisamide (Empatic)
The combination of bupropion and zonisamide (Empatic) is being developed for the treatment of obesity. A proof of concept trial with placebo, 300 mg/day of bupropion, 400 mg of zonisamide, and the combination was reported in abstract form (Greenway et al., 2006b ). This 6-month study in 220 subjects gave initial body weight losses of Ϫ0.4, Ϫ3.6, Ϫ6.6 , and Ϫ9.2% in the placebo, bupropion, zonisamide, and bupropion-zonisamide groups, respectively. The bupropion-zonisamide group lost 12% of initial body weight at 48 weeks. Adverse events with prevalence Ͼ10% included insomnia, nausea, fatigue, upper respiratory infection, headache, and anxiety. Tolerability may be improved by dosage modification. Topiramate and Phentermine (Qnexa) A combination of phentermine and topiramate (Qnexa) is being developed for the treatment of obesity . A 6-month study in 200 subjects gave an Ϫ11.4-kg weight loss in the phentermine-topiramate group and a Ϫ2.3-kg weight loss in the placebo group. More than half of the phentermine-topiramate subjects lost 10% of their initial body weight. The dropout rate in the phentermine-topiramate group was 8% compared with 38% in the placebo group (2006).
J. Combination of
VII. Drugs in the Early Phases of Development
A. Melanin-Concentrating Hormone Receptor-1 Antagonist
Melanin-concentrating hormone and ␣-melanocytestimulating hormone have opposite effects on skin coloration in fish. Melanin-concentrating hormone blocks the effects of ␣-melanocyte-stimulating hormone on food 
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BRAY AND GREENWAY intake when both are injected into the cerebral ventricles of rats (Ludwig et al., 1998) . Melanin-concentrating hormone has two receptors MCH-1 and MCH-2. Mice without the MCH-1 receptor have increased activity, increased temperature, and increased sympathetic tone (Astrand et al., 2004) . Overexpression of the MCH-1 receptor and chronic infusion of an MCH-1 agonist cause enhanced feeding, caloric efficiency, and weight gain, whereas an MCH-1 antagonist reduces food intake and body weight gain without an effect on lean tissue (Shearman et al., 2003) . MCH-1 antagonists reduce food intake by decreasing meal size and also act as antidepressants and anxiolytics (Borowsky et al., 2002; Kowalski et al., 2004 ). An orally active MCH-1 receptor antagonist that has good plasma levels and central nervous system exposure induced weight loss in obese mice with chronic treatment (Souers et al., 2005) . A number of other MCH-1 antagonists reduce food intake and body weight in experimental animals (Handlon and Zhou, 2006) . No human studies have been reported.
B. Histamine-3 Receptor Antagonists
Histamine and its receptors can affect food intake. Among the antipsychotic drugs that produce weight gain, binding to the H1 receptor is higher than with any other monoamine receptor and histamine reduces food intake by acting on this receptor (Kroeze et al., 2003) . The search for drugs that can modulate food intake through the histamine system has focused on the histamine H3 receptor, which is an autoreceptor; that is, activation of this receptor inhibits histamine release, whereas blockade of the receptor increases histamine release. Both imidazole and nonimidazole antagonists of the H3 receptor have been published and shown to reduce food intake and body weight gain in experimental animals (Leurs et al., 2005; Nilsson, 2006) .
Betahistine was approved for the treatment of vertigo in the United States when only demonstration of safety was required but was removed from the market in the early 1970s after the U.S. Food and Drug Administration began requiring proof of efficacy. Betahistine has continued to be used and well tolerated in other countries to the present day and is now understood to stimulate the histamine-1 receptor through antagonism at the histamine-3 receptor (Tighilet et al., 2002) . Betahistine decreases food intake in rats in a dose-dependent manner, both orally and parenterally (Szelag et al., 2001) . Water intake was stimulated and food intake was suppressed by betahistine given parenterally to pygmy goats (Rossi et al., 1999) . Betahistine was given to three human subjects at 48 mg t.i.d. in conjunction with 10 mg/day of olanzapine in the treatment of new-onset schizophrenia. There was a 3.1 Ϯ 0.9-kg weight gain in the first 2 weeks, but no subsequent weight gain over the next month of treatment, and betahistine did not affect the antipsychotic effect of olanzapine (Poyurovsky et al., 2004) . Betahistine has also been shown to improve arteriosclerotic dementia (Pathy et al., 1977; Seipel et al., 1977) .
C. Ghrelin Antagonists
Ghrelin is a small peptide synthesized in the stomach. Its active form contains an octanoate on the third amino acid. The level rises with fasting and declines after eating, suggesting that it may be a satiety signal. Chronic administration produces hyperphagia and weight gain in animals. Moreover, obese subjects have lower levels than normal-weight individuals.
Ghrelin acts at the growth hormone secretogogue receptor to produce its effects. A group of growth hormonestimulating peptides that also act on this growth hormone secretogogue receptor are known to increase food intake in human subjects (Laferrere et al., 2005) . Antagonists to this receptor might thus be useful drugs for treating overweight patients; this theory is supported by suppression of food intake and attenuated weight regain in diet-induced obese mice treated with such drugs.
D. Angiogenesis Antagonists and Fat Cell Antibodies
Formation of an enlarging fat organ requires new blood vessels, and the concept of inhibiting the growth of these vessels and thus showing fat cell growth is an intriguing possibility. Experimental studies in mice have shown that an antagonist of angiogenesis can inhibit fat cell development in ob/ob mice (Rupnick et al., 2002; Brakenhielm et al., 2004) . The discovery that fumagillin, isolated from the fungus Aspergillus fumigatus, inhibits blood vessel growth has provided a platform for development of new drugs. Fumagillol has provided one derivative, TNP-470, that has been tested by Rupnick et al. (2002) . This study showed that TNP-470 reduces body weight and slightly decreases food intake in animal models of obesity.
VIII. Drugs and Herbal Medications No Longer under Investigation or Withdrawn
A. Ephedra
Ephedrine combined with methylxanthines were used in the treatment of asthma for decades. A physician in Denmark noted weight loss in his patients taking this combination drug for asthma. The combination of 200 mg of caffeine and 20 mg of ephedrine given three times a day was subsequently approved as a prescription medication for overweight in Denmark, where it had commercial success for more than a decade (Greenway, 2001) . In 1994, legislation in the United States declared ephedra and caffeine to be foods, eligible to be sold as dietary herbal supplements. The use of this combination as an unregulated dietary supplement for the treatment of overweight was accompanied by reports of cardiovascular and neuropsychiatric adverse events leading to the FDA declaring ephedra, the herbal form of ephedrine, as an adulterant (Shekelle et al., 2003) . Recently, courts in DRUG TREATMENT OF OBESITY the United States have overturned the FDA decision to withdraw ephedra from the herbal market, at least in regard to ephedra doses of Յ10 mg, but the implications that this legal decision may have on the availability of ephedra in the herbal dietary supplement market remains to be determined. A recent small-size, 9-month, randomized, placebo-controlled trial (Hackman et al., 2006) showed that subjects taking an herbal preparation containing ephedra, green tea extract, guarana (caffeine source), Garcinia cambogia and other botanicals, plus a high-potency multivitamin/mineral pill plus a capsule with n-3 fatty acids lost Ϫ7.18 kg in 9 months compared with Ϫ2.25 kg in the placebo group. This result suggests that the market for ephedra combinations with other botanicals may still be alive.
B. ␤ 3 -Adrenergic Agonists
In the early 1980s, the ␤ 3 -adrenergic receptor was identified and shown in animals to increase lipolysis, fat oxidation, energy expenditure and insulin action when stimulated. Selective ␤-adrenergic agonists based on the rodent ␤ 3 -adrenergic receptor were not selective in humans, and the human ␤ 3 -adrenergic receptor was subsequently cloned and found to be only 60% homologous with that of rodents (de Souza and Burkey, 2001) . A ␤ 3 -adrenergic agonist selective for the human ␤ 3 -receptor, L-796568, increased lipolysis and energy expenditure when given as a single 1000-mg dose to overweight men without significant stimulation of the ␤ 2 -adrenergic receptor . A 28-day study with the same compound at 375 mg/day versus a placebo in obese men gave no significant increase in energy expenditure, reduction in respiratory quotient, or changes in glucose tolerance. There was a significant reduction of triglycerides, however. This lack of a chronic effect was interpreted as either a lack of recruitment of ␤ 3 -responsive tissues, a down-regulation of ␤ 3 -receptors, or both (Larsen et al., 2002) . Thus, despite encouraging results from rodents, human trials of selective ␤ 3 -agonists have been disappointing.
C. Bromocriptine
Hibernating and migratory animals change their ability to store and burn fat on the basis of circadian rhythms, and these circadian rhythms are controlled by prolactin secretion. It has been postulated that overweight and diabetic individuals have abnormal circadian rhythms. These abnormal rhythms favor fat storage and insulin resistance. Rapid-release bromocriptine (Ergocet), given at 8 A.M, has been postulated to reverse this abnormal circadian rhythm and effectively treat diabetes and overweight. An uncontrolled trial of quickrelease bromocriptine given orally for 8 weeks significantly decreased 24-h plasma glucose, free fatty acid, and triglyceride levels from baseline (Kamath et al., 1997) . This was followed by a controlled trial in which 22 diabetic subjects were randomized to quick-release bromocriptine or placebo. Hemoglobin A 1c fell from 8.7to 8.1% in the bromocriptine group and rose from 8.5 to 9.1% in the placebo group, a statistically significant difference (Pijl et al., 2000) . In an uncontrolled trial, 33 overweight postmenopausal women reduced their body fat by 11.7% measured by skinfold thickness over 6 weeks of treatment with quick-release bromocriptine (Meier et al., 1992) . This was followed by a controlled trial in which 17 overweight subjects were randomized to rapid-release bromocriptine (1.6 -2.4 mg/day) or a placebo for 18 weeks. The bromocriptine group lost significantly more weight (6.3 kg versus 0.9 kg) and more fat as measured by skinfold thicknesses (5.4 kg versus 1.5 kg) (Cincotta and Meier, 1996) . The company developing Ergocet received an approvable determination by the FDA for quick-release bromocriptine to treat diabetes but was asked to do additional safety studies. These studies were never performed, and the obesity development program proceeded no further.
D. Ecopipam
Ecopipam is a dopamine 1 and 5 receptor antagonist that was originally studied for the treatment of cocaine addiction (Nann-Vernotica et al., 2001) . Ecopipam was in development as a drug to treat overweight, but its development was terminated (Bays and Dujovne, 2002) .
There were four randomized, double-blind, multicenter trials comparing ecopipam (n ϭ 1667) and placebo (n ϭ 1118) in obese subjects including type 2 diabetic subjects. Subjects received 10, 30, or 100 mg of oral ecopipam q.d. for 12 weeks (phase 2) or 50 or 100 mg q.d. for 52 weeks (phase 3). In the phase 3 studies, 100 mg of ecopipam produced a 3.1 to 4.3% greater weight loss than placebo at 52 weeks. Phase 3 studies were discontinued because of unexpected psychiatric adverse events (ecopipam 31% versus placebo 15%) including depression, anxiety, and suicidal ideation (Astrup et al., 2007) .
E. Axokine
Axokine is a derivative of ciliary neurotrophic factor that, like leptin, acts through the STAT signaling pathway in the brain (Anderson et al., 2003 ). Axokine has been tested in two phase II studies, one in overweight patients and one in diabetic patients, and a phase III study in overweight patients. The first multicenter 12-week phase II study randomized 170 obese subjects with a BMI between 35 and 50 kg/m 2 . The optimal dose was 1 g/kg, and this group lost Ϫ4.6 kg compared with a weight gain of ϩ0.6 kg in the placebo group (Ettinger et al., 2003) . The second 12-week phase II study randomized 107 obese type 2 diabetic subjects with a BMI between 35 and 50 kg/m 2 (http://www. regeneron.com/ company/press_detail.asp?v_c_idϭ170) . Those subjects treated with the 1.0-g/kg dose of axokine lost Ϫ3.2 kg compared with Ϫ1.2 kg in the placebo group (P Ͻ 0.01).
The 1-year phase III trial with a 1-year open label extension randomized 501 subjects to placebo and 1467 subjects to axokine at a dose of 1 g/kg/day (http:// www.regeneron.com). Subjects had a BMI between 30 and 55 kg/m 2 , if their overweight was uncomplicated, or between 27 and 55 kg/m 2 , if their overweight was complicated by hypertension or dyslipidemia. At the end of 1 year, the axokine group lost Ϫ3.6 kg compared with Ϫ2.0 kg in the placebo group (P Ͻ 0.001), a difference that does not meet the FDA efficacy criteria for approval. The most common adverse events were mild and included injection site reactions, nausea, and cough. The most concerning finding, however, was that two-thirds of those receiving axokine developed antibodies after 3 months that limited weight loss, and there was no way to prospectively predict those who would develop antibodies. Development of axokine has been terminated.
IX. Over-the-Counter Medications
A. Orlistat
Orlistat at a dose of 60 mg/day is an over-the-counter preparation for overweight individuals. This preparation has been approved by the FDA and is marketed under the trade name Alli to be used by overweight adults for up to 6 months along with a weight loss program.
B. Phenylpropanolamine
Short-term weight loss with phenylpropanolamine was similar to the short-term weight losses seen with prescription drugs for overweight (Greenway, 1992) . The longest study of phenylpropanolamine lasted 20 weeks and produced a Ϫ5.1-kg weight loss in the drug group compared with Ϫ0.4-kg weight loss in the placebo group, which was Ͼ5% compared with placebo (Schteingart, 1992) . Although phenylpropanolamine had a long history of safety in clinical trials dating to the 1930s, it was taken off the market because of an association with hemorrhagic stroke in women (Kernan et al., 2000) .
X. Herbal Products, Functional Foods, and Nutriceuticals
Two recent articles have examined randomized clinical trials for complementary therapies for reducing body weight (Dwyer et al., 2005; Pittler and Ernst, 2005) .
A. Interventions Requiring Special Training
1. Acupuncture/Acupressure. Acupuncture consists of placing needles at key points controlling neural connections for relief of pain and other clinical purposes. Pittler and Ernst (2005) identified four randomized, controlled trials in which sham treatments were used. Two of the randomized trials of acupuncture reported a reduction in hunger, whereas two others showed no differences in body weight. Overall, the evidence does not support a specific acupuncture procedure that works.
Homeopathy.
Two different preparations have been used in homeopathic doses to treat overweight, and they were reflected in two randomized, controlled trials. Helianthus tuberoses D1 was investigated for 3 months in one trial in which those receiving the active ingredient lost Ϫ7.1 kg, which was significantly more than in the placebo group. In a second trial, a single dose of Thyroidinum 30cH was given to fasting patients, but it was no more effective than placebo.
3. Hypnotherapy . Hyponotherapy has been examined in six randomized, controlled trials in which hypnotherapy plus cognitive behavior therapy was compared with cognitive behavior therapy alone. The addition of hyponotherapy to cognitive behavior therapy adds a small, but significant, weight loss to the cognitive behavior therapy (Pittler and Ernst, 2005) .
B. Minerals and Metabolites
Chromium Picolinate.
Chromium is a trace mineral and a cofactor to insulin. It has been claimed that chromium can cause weight loss and fat loss while increasing lean body mass. A recent meta-analysis of 10 double-blind, randomized, controlled trials in participants with a BMI between 28 and 33 kg/m 2 , showed a statistically significant weight loss of 1.1 to 1.2 kg over a 6-to 14-week treatment period. There were no adverse events, but the authors pointed out that this weight loss, although statistically significant, was not clinically significant (Pittler and Ernst, 2004) . These data have to be interpreted cautiously, because they rely heavily on one robust study . Cefalu et al. (2002) in a review of the field have shown that chromium picolinate may have a significant effect in preventing weight regain. Dwyer et al. (2005) concluded that there is little evidence of benefit and few or no adverse events.
2. Hydroxymethyl Butyrate. ␤-Hydroxy-␤-methylbutyrate is a metabolite of leucine. It acts in vivo to inhibit the breakdown of protein. In a literature review, Pittler and Ernst (2005) found two randomized, controlled trials that reported significant differences in fat mass reduction and at least a trend toward an increase in lean body mass. Further studies are clearly needed.
Pyruvate.
Pyruvate is an intermediary in the metabolism of glucose and also serves as a hydrogen shuttle between liver and muscle. It has been suggested to improve exercise performance and body composition at 7 to 20% of dietary calories but is sold as a dietary herbal supplement for obesity at a dose of ϳ3 g/day. Pittler and Ernst (2005) identified two randomized, controlled trials that included subjects with a BMI of Ն25 kg/m 2 . There were no significant effects on body weight reduction compared with placebo. They concluded that the case for pyruvate as a dietary herbal supplement is weak.
4. Conjugated Linoleic Acid. The word "conjugated" in linoleic acid refers to the position of the double bond between carbons 9 and 11 or 10 and 12. There are DRUG TREATMENT OF OBESITY differences in effects of each of the isomeric combinations. In an analysis of 13 randomized, controlled trials lasting Յ6 months Larsen et al. (2003) reported that there was little evidence that conjugated linoleic acid produced weight loss in humans, although one report suggested that it lowers body fat without an effect on body weight (Riserus et al., 2004) . There is also concern about liver toxicity from the trans-10, cis-12 isomer and the induction of insulin resistance. Dwyer et al. (2005) concluded that there is little evidence of benefit.
5. Calcium. Nearly 20 years ago McCarron et al. (1984) reported that there was a negative relationship between body mass index and dietary calcium intake in the data collected by the National Center for Health Statistics. More recently Zemel et al. (2000) found that there was a strong inverse relationship between calcium intake and the risk of being in the highest quartile of body mass index. These studies have prompted a reevaluation of studies measuring calcium intake or giving calcium orally.
The relationship of calcium and body weight is problematic, however, because a patent was issued for the effects of dairy products for producing weight loss to one of the proponents of this approach. Such a relationship in which monetary gain is associated with publication of positive studies raises concerns when one is reading the published studies. Moreover, there is inconsistency in both the animal and human studies.
In one small clinical trial, increasing dietary intake of calcium by adding 800 mg/day of supplemental calcium to a diet containing 400 to 500 mg/day was claimed to augment weight loss and fat loss on reducing diets (Zemel et al., 2004) . In two small studies in African-American adults Zemel et al. (2005b) claimed that substitution of calcium-rich foods in isocaloric diets reduced adiposity and improved metabolic profiles during a 24 week trial. In another small study Zemel et al. (2005a) randomized 34 subjects to receive a control calcium diet with 400 to 500 mg/day (n ϭ 16) or a yogurt-supplemented diet (n ϭ 18) for 12 weeks. In this small, shortduration study, fat loss was greater with the yogurt diet (Ϫ4.43 kg) than with the control diet (Ϫ2.75 kg). On the basis of these data, they claim that yogurt enhances central fat loss. In a large multicenter trial that enrolled nearly 100 subjects, the same authors claimed that a hypocaloric diet with calcium supplemented to the level of 1400 mg/day did not significantly improve weight loss or body composition compared with a diet with lower calcium intake (600 mg/day), whereas a diet with three servings per day of dairy products augmented weight and fat loss (Zemel et al., 2005b) .
Increasing supplemental calcium from 0 to nearly 2000 mg/day was associated with a reduction in BMI of ϳ5 BMI units (Davies et al., 2000) . These data might suggest that low calcium intake was playing a role in the current epidemic of overweight. However, three controlled clinical trials have failed to show an effect of calcium on weight loss, leaving the issue in limbo (Shapses et al., 2001 (Shapses et al., , 2004 Barr, 2003) . Dwyer et al. (2005) concluded that the evidence of benefit is equivocal and limited to small trials, but there are no major concerns regarding adverse events.
C. Herbal Dietary Supplements
1. Ephedra sinica. E. sinica is an evergreen that grows in central Asia, and its principal ingredient is ephedrine (see also Section VIII. A.) . Ephedrine with caffeine has been shown to produce weight loss in randomized, placebo-controlled clinical trials (Astrup et al., 1992) . The ephedra alkaloids from ma huang contain ephedrine, and three randomized placebo-controlled clinical trials, one for 2 months, one for 3 months, and one for 6 months showed significantly greater weight loss than with placebo (Boozer et al., 2001 ). Ephedracontaining herbal preparations were removed from the market by the U.S. Food and Drug Administration in April 2004 because of alleged harmful cardiovascular side effects (Shekelle et al., 2003) , but this act, as stated above, has recently been reversed.
Green Tea Extract.
Green tea extract is a common ingredient in dietary herbal supplements for weight loss, and it contains catechins and caffeine. Green tea catechins such as epigallocatechin gallate inhibit catechol-O-methyl transferase, the enzyme that degrades norepinephrine (Borchardt and Huber, 1975) . In vitro brown fat cell experiments show catechins and caffeine to be synergistic in stimulating thermogenesis (Dulloo et al., 2000) . Subjects given green tea capsules three times a day with a total of 150 mg of caffeine and 375 mg of catechins of which 270 mg was epigallocatechin gallate had a 4.5% increase in 24-h metabolic rate in a metabolic chamber and a 3.2% increase with caffeine alone compared with placebo. Fat oxidation was increased, and green tea extract increased 24-h metabolic rate 328 kJ/ day (ϳ80 kcal/day) (Dulloo et al., 1999) . Another study by Belza and Jessen (2005) showed a statistically significant 200 kJ/day increase in metabolic rate in a metabolic chamber study with a combination of capsaicin, green tea extract, tyrosine, and calcium.
Clinical trials for weight loss are much less encouraging. Chantre and Lairon (2002) reported a 4.6% weight loss over 12 weeks in an open-label study, 2002), but a placebo-controlled study of green tea extract in subjects with polycystic ovarian disease gave a 2.4% weight loss over 3 months that was not significantly greater than the loss with placebo, and there were no improvements in glucose or lipid metabolism (Chan et al., 2006) . Kovacs et al. (2004) found that green tea extract was no better than placebo in maintaining a 7.5% weight loss over 13 weeks. This result was confirmed in a similar weight maintenance study by Westerterp et al. (2005) . Thus, green tea extract seems to have little potential as a treatment for obesity.
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BRAY AND GREENWAY 4. Plantago psyllium. The psyllium extract from the seeds of this plant is a water soluble fiber. In one randomized, placebo-controlled trial identified by Pittler and Ernst (2005) there was no significant change in body weight in either the treatment or placebo group.
XI. Conclusions
Although the drugs presently available for the treatment of overweight patients are few in number and limited in efficacy, the pipeline for drug development is very rich. Because drug development is more sophisticated today than in the past, we anticipate that the development of safe and effective drugs for the treatment of overweight will proceed at a more rapid pace than was the case for other chronic diseases that presently have safe and effective medications, such as hypertension and diabetes.
